[go: up one dir, main page]

US5703085A - Xanthine derivatives - Google Patents

Xanthine derivatives Download PDF

Info

Publication number
US5703085A
US5703085A US08/537,770 US53777095A US5703085A US 5703085 A US5703085 A US 5703085A US 53777095 A US53777095 A US 53777095A US 5703085 A US5703085 A US 5703085A
Authority
US
United States
Prior art keywords
compound
sub
lower alkyl
compounds
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/537,770
Inventor
Fumio Suzuki
Nobuaki Koike
Junichi Shimada
Joji Nakamura
Shizuo Shiozaki
Shigeto Kitamura
Shunji Ichikawa
Hiroshi Kase
Hiromi Nonaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Assigned to KYOWA HAKKO KOGYO CO., LTD. reassignment KYOWA HAKKO KOGYO CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KITAMURA, SHIGETO, NAKAMURA, JOJI, ICHIKAWA, SHUNJI, KASE, HIROSHI, KOIKE, NOBUAKI, NONAKA, HIROMI, SHIMADA, JUNICHI, SHIOZAKI, SHIZUO, SUZUKI, FUMIO
Application granted granted Critical
Publication of US5703085A publication Critical patent/US5703085A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Definitions

  • the present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof which have adenosine A 2 receptor antagonistic activity and are useful for the treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A 2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).
  • diseases caused by hyperergasia of adenosine A 2 receptors for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis.
  • adenosine exhibits neurotransmitter depressing activity Eur. J. Pharmacol., 168, 285 (1989)!, bronchospasmic activity Br. J. Pharmacol., 100, 251(1990)!, bone absorption promoting activity Acta Physiol. Scand., 131, 287(1987)!, and the like, via A 2 receptors.
  • adenosine A 2 receptor antagonists (hereinafter referred to as A 2 -antagonists) are expected as therapeutic or preventive agents for various kinds of diseases caused by hyperergasia of adenosine A 2 receptors, for example, therapeutic agents for Parkinson's disease, antidementia agents, antidepressants, anti-asthmatic agents, and therapeutic agents for osteoporosis.
  • a 2 -antagonists adenosine A 2 receptor antagonists
  • 26516/72 discloses, as cerebral stimulants, compounds represented by Formula (B) in which R 1b and R 2b independently represent methyl or ethyl, R 3b represents methyl, y 1b and y 2b represent hydrogen, and Z b represents phenyl or 3,4,5-trimethoxyphenyl.
  • Formula (B) in which R 1b and R 2b independently represent methyl or ethyl, R 3b represents methyl, y 1b and y 2b represent hydrogen, and Z b represents phenyl or 3,4,5-trimethoxyphenyl.
  • WO92/06976 discloses, as compounds having an adenosine A 2 receptor antagonistic activity and therapeutic effects on asthma and osteoporosis, compounds represented by Formula (B) in which R 1b and R 2b independently represent hydrogen, propyl, butyl, or allyl, R 3b represents hydrogen or lower alkyl, y 1b and y 2b independently represent hydrogen or methyl, and Z b represents substituted or unsubstituted phenyl, pyridyl, imidazolyl, furyl, or thienyl.
  • Formula (B) in which R 1b and R 2b independently represent hydrogen, propyl, butyl, or allyl, R 3b represents hydrogen or lower alkyl, y 1b and y 2b independently represent hydrogen or methyl, and Z b represents substituted or unsubstituted phenyl, pyridyl, imidazolyl, furyl, or thienyl.
  • adenosine A 2 receptor antagonistic activity is found in compounds represented by Formula (B) in which R 1b and R 2b independently represent methyl, ethyl, propyl, or allyl, R 3b represents hydrogen or methyl, y 1b and y 2b represent hydrogen, and Z b represents substituted or unsubstituted phenyl J. Med. Chem., 36, 1333 (1993)!.
  • R 1b , R 2b and R 3b represent methyl
  • y 1b and y 2b represent hydrogen
  • Z b represents substituted or unsubstituted phenyl J. Med. Chem., 36, 1333 (1993)!.
  • Z b represents substituted or unsubstituted phenyl J. Med. Chem., 36, 1333 (1993)!.
  • Z b represents phenyl (8-styryl caffeine
  • the present invention relates to xanthine derivatives and pharmaceutically acceptable salts thereof represented by Formula (I): ##STR3## in which R 1 , R 2 , and R 3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl, R 4 represents lower alkyl, or substituted or unsubstituted aryl, R 5 and R 6 independently represent hydrogen, lower alkyl, and lower alkoxy, or R 5 and R 6 are combined together to represent --O--(CH 2 )p--O-- (p is an integer of 1 to 3), n represents 0,1, or 2, and m represents 1 or 2.
  • R 1 , R 2 , and R 3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl
  • R 4 represents lower alkyl, or substituted or unsubstituted aryl
  • R 5 and R 6 independently represent hydrogen, lower alkyl, and lower alkoxy, or R 5 and R 6 are combined together to represent --O-
  • lower alkyl and the alkyl moiety of lower alkoxy mean straight-chain or branched alkyl group having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl and hexyl;
  • lower alkenyl means straight-chain or branched alkenyl group having 2-6 carbon atoms such as vinyl, allyl, methacryl, crotyl, 3-butenyl, 2-pentenyl, 4-pentenyl, 2-hexenyl and 5-hexenyl;
  • lower alkynyl means a straight-chain or branched alkynyl group having 2 to 6 carbon atoms such as ethynyl, propargyl, 2-butynyl, 3-butynyl, 2-pentynyl, 4-
  • Each of the substituents for aryl has 1 to 4 substitutions, and examples of which are substituted or unsubstituted lower alkyl, hydroxy, substituted or unsubstituted lower alkoxy, halogen, nitro, amino, lower alkylamino, di-lower alkylamino, benzyloxy, phenyl, and phenoxy.
  • the lower alkyl, and the alkyl moiety of lower alkoxy, lower alkylamino and di-lower alkylamino have the same meanings as the lower alkyl defined above, and the halogen represents an atom of fluorine, chlorine, bromine, or iodine.
  • Each of the substituents for lower alkyl and lower alkoxy has 1 to 3 substitutions, and examples of which are halogen, nitro, lower alkoxy and amino, wherein halogen and lower alkoxy have the same meanings as defined above.
  • the pharmaceutically acceptable salts of Compounds (I) include pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts and amino acid addition salts.
  • the pharmaceutically acceptable acid addition salts include inorganic salts such as hydrochloride, sulfate, and phosphate, and organic salts such as acetate, maleate, fumarate, tartrate and citrate.
  • the pharmaceutically acceptable metal salts include alkaline metal salts such as sodium salt and potassium salt, and alkali earth metal salts such as magnesium salt and calcium salt, aluminium salt, and zinc salt.
  • the pharmaceutically acceptable ammonium salts include salts of ammonium and tetramethyl ammonium.
  • the pharmaceutically acceptable organic amine addition salts include salts with morphorine and piperidine.
  • the pharmaceutically acceptable amino acid addition salts include salts with lysine, glycine and phenylalanine.
  • Compounds (III) can be prepared by dealkylation of Compounds (II) obtained by known methods (e.g., WO92/06976).
  • Examples of preferable dealkylation agent are boron tribromide and its dimethyldisulfide complex, boron trichloride, iodotrimethylsilane, sodium ethanethiolate, sodium benzenthiolate, gas of hydrogen chloride, hydrochloric acid and hydrobromic acid.
  • the reaction solvent varying depending on the dealkylation agent employed, is selected from aromatic hydrocarbons such as toluene and xylene, halogenohydrocarbons such as methylene chloride, chloroform and ethane dichloride, ethers such as dioxane and tetrahydrofuran, alcohols such as methanol and ethanol, dimethylformamide and acetic acid.
  • aromatic hydrocarbons such as toluene and xylene
  • halogenohydrocarbons such as methylene chloride, chloroform and ethane dichloride
  • ethers such as dioxane and tetrahydrofuran
  • alcohols such as methanol and ethanol, dimethylformamide and acetic acid.
  • Compounds (I) wherein n is 0 can be obtained by reacting Compounds (III) with carboxylic acid (IV) or its reactive derivatives.
  • the reactive derivatives of Compounds (IV) include acid halides such as acid chloride and acid bromide, activated esters such as p-nitrophenyl ester and N-oxysuccinimide, acid anhydrides which are commercially available or which are produced using carbodiimide such as 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide, diisopropylcarbodiimide and dicyclohexylcarbodiimide, and mixed acid anhydrides with monoethyl carbonate, monoisobutyl carbonate.
  • acid halides such as acid chloride and acid bromide
  • activated esters such as p-nitrophenyl ester and N-oxysuccinimide
  • acid anhydrides which are commercially available or which are produced using carbodiimide such as 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide, diisopropylcarbodiimide and dicyclo
  • reaction is carried out at 50° to 200° C. in the absence of solvent, and completed in 10 minutes to 5 hours.
  • the reaction can be carried out according to a method conventionally used in peptide chemistry. That is, Compounds (I), wherein n is 0, can be obtained by reacting Compounds (III) with the reactive derivatives of Compounds (IV) preferably in the presence of an additive or base.
  • the reaction solvent is suitably selected from halogenohydrocarbons such as methylene chloride, chloroform and ethane dichloride, ethers such as dioxane and tetrahydrofuran, dimethylformamide, dimethylsulfoxide, water, etc.
  • the additive includes 1-hydroxybenzotriazole.
  • Compounds (I) wherein n is 1 or 2 can be obtained by reacting Compounds (III) with alkylation agent (V) in the presence of a base, if necessary.
  • the base includes alkaline metal carbonates such as sodium carbonate and potassium carbonate, alkaline metal hydrides such as sodium hydride, and alkaline metal alkoxides such as sodium methoxide and sodium ethoxide.
  • alkaline metal carbonates such as sodium carbonate and potassium carbonate
  • alkaline metal hydrides such as sodium hydride
  • alkaline metal alkoxides such as sodium methoxide and sodium ethoxide.
  • aromatic hydrocarbons such as toluene and xylene, ketones such as acetone and methylethylketone, dimethylformamide, dimethylsulfoxide, etc.
  • the reaction is carried out at 0° to 180° C. and is completed in 0.5 to 24 hours.
  • the desired compounds prepared according to the process described above can be isolated and purified by purification methods conventionally used in organic synthetic chemistry such as filtration, extraction, washing, drying, concentration, recrystallization and various kinds of chromatographies.
  • Compounds (I) can exist in the form of geometrical isomers such as an (E)-isomer and a (Z)-isomer, and the present invention covers all possible isomers including these geometrical isomers and mixtures thereof.
  • geometrical isomers such as an (E)-isomer and a (Z)-isomer
  • the present invention covers all possible isomers including these geometrical isomers and mixtures thereof.
  • separation between an (E)-isomer and a (Z)-isomer is desired, they can be isolated and purified by fractionation methods, for example, fractional crystallization, fractional precipitation, fractional dissolution, and various kinds of chromatographies.
  • Compounds (I) and pharmaceutically acceptable salts thereof may exist in the form of an adduct with water or various kinds of solvents, which are also within the scope of the present invention.
  • Adenosine Receptor Antagonistic Activity (Adenosine A 2 Receptor Binding Test)
  • Corpus striatum of a rat was suspended in ice-cooled 50 mM Tris (hydroxymethyl) aminomethane hydrochloride (Tris HCl) buffer (pH 7.7) by using Polytron homogenizer (manufactured by Kinematica Co.). The suspension was centrifuged (50,000 ⁇ g, 10 minutes), and the precipitate was suspended again in the same amount of 50 mM Tris HCl buffer. The suspension was centrifuged under the same conditions, and the final precipitate was suspended in 50 mM Tris HCl buffer containing 10 mM magnesium chloride and 0.02 unit/mg tissue of adenosine deaminase (manufactured by Sigma Co.)! to give a tissue concentration of 5 mg (wet weight)/ml.
  • Tris HCl Tris (hydroxymethyl) aminomethane hydrochloride
  • Polytron homogenizer manufactured by Kinematica Co.
  • the filter was immediately washed three times with 5 ml each of ice-cooled 50 mM Tris HCl buffer, and transferred to a vial, and a scintillator (EX-H; manufactured by Wako Pure Chemical Industries, Ltd.) was added thereto.
  • the radioactivity on the filter was determined with a liquid scintillation counter (manufactured by Packard Instrument Co.).
  • T Amount of the total binding.
  • N Amount of the nonspecific binding.
  • Amount of the total binding means the amount of radioactivity of 3 H-CGS 21680 bound in the absence of the test compound.
  • Amount of the nonspecific binding means the amount of radioactivity of 3 H-CGS 21680 bound in the presence of 100 ⁇ M cyclopentyladenosine (CPA; manufactured by Sigma Co.).
  • Amount of the binding in the presence of the test compound means the amount of radioactivity of 3 H-CGS 21680 bound in the presence of the test compound at various levels of concentrations.
  • Compounds (I) and pharmaceutically acceptable salts thereof exhibit a potent adenosine A 2 receptor antagonistic activity. Thus, they are effective against various kinds of diseases caused by hyperergasia of adenosine A 2 receptors (for example, Parkinson's disease, senile dementia, asthma, and osteoporosis).
  • diseases caused by hyperergasia of adenosine A 2 receptors for example, Parkinson's disease, senile dementia, asthma, and osteoporosis.
  • Parkinson's disease is a clinical syndrome caused by degeneration and cell death of nigrostriatal dopaminergic neurons.
  • Administration of haloperidol induces catalepsy resulting from the blockade of postsynaptic dopamine D 2 receptors. It is generally accepted that this haloperidol-induced catalepsy is a classical model to reproduce drug-induced Parkinson's disease Eur. J. Pharmacol., 182, 327 (1990).
  • mice weighing 22 to 24 g, Japan SLC
  • Haloperidol manufactured by Janssen Pharmaceutica
  • CMC calf serum
  • test compound was suspended in injectable distilled water (manufactured by Otsuka Pharmaceutical Co., Ltd.) after adding Tween 80 polyoxyethylene (20) sorbitan monooleate!.
  • L-DOPA manufactured by Kyowa Hakko Kogyo Co., Ltd.
  • benserazide hydrochloride manufactured by Kyowa Hakko Kogyo Co., Ltd.
  • Tween 80 One hour after the intraperitoneal administration of haloperidol, the suspension containing the test compound or the suspension containing no test compound injectable distilled water (manufactured by Otsuka Pharmaceutical Co., Ltd.) containing Tween 80; control! were orally administered to the separate groups of the mice (0.1 ml per 10 g of body weight).
  • test compound One hour after the administration of the test compound, the forelimbs of each mouse and subsequently the hindlimbs of the same mouse were placed on a 4.5 cm-high, 1.0 cm-wide bar and catalepsy was estimated. All of the test compounds were orally administered at a dose of 10 mg/kg, and L-DOPA (100 mg/kg) and benserazide (25 mg/kg) were intraperitoneally administered together as a control. The catalepsy score and the standard of judgment are shown below.
  • the effect of the compounds was evaluated by the total of the catalepsy scores of 5 or 10 mice in each group (25 or 50 points at the maximum).
  • the groups wherein the total score was not more than 20 or 40 points were estimated to be effective.
  • the number of the animals showing remission against catalepsy is the number of the mice for which the catalepsy score was not more than 4 points in 5 or 10 mice.
  • the remission rate against catalepsy shows the rate of decrease in the total score based on that of the control group.
  • the experiment was performed using several groups of male ddY mice weighing 20 to 25 g (Japan SLC), each group consisting of two mice.
  • a test compound was suspended in injectable distilled water (manufactured by Otsuka Pharmaceutical Co., Ltd.) after adding Tween 80.
  • Clonidine hydrochloride (manufactured by Sigma Co.) was dissolved in physiological saline solution (manufactured by Otsuka Pharmaceutical Co., Ltd.).
  • the suspension containing the test compound and the suspension containing no test compound (control) were orally administered to the separate groups of the mice (0.1 ml per 10 g of body weight).
  • clonidine hydrochloride (20 mg/kg) was intraperitoneally administered. The number of biting attacks during the 30 minutes immediately after the clonidine treatment was counted. The effect of the compounds was evaluated by comparing the number of biting attacks of the test compound-administered groups with that of control groups (significance test: Student' t-test).
  • compositions in accordance with the present invention can be prepared by uniformly mixing an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, as an active ingredient, with pharmaceutically acceptable carriers. It is desired that such pharmaceutical compositions are prepared in a unit dose form suitable for oral administration or administration through injection.
  • any useful pharmaceutically acceptable carrier may be used.
  • liquid preparations for oral administration such as a suspension and syrup can be prepared using water, sugars such as sucrose, sorbitol and fructose, gycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil and soybean oil, preservatives such as p-hydroxybenzoates, flavors such as strawberry flavor and peppermint, and the like.
  • Powders, pills, capsules, and tablets can be prepared using excipients such as lactose, glucose, sucrose, and mannitol, disintegrating agents such as starch and sodium alginate, lubricants such as magnesium stearate and talc, binders such as polyvinyl alcohol, hydroxypropyl cellulose, and gelatin, surfactants such as fatty acid esters, plasticizers such as glycerin, and the like. Tablets and capsules are the most useful oral unit dose forms because of the readiness of administration. For preparing tablets and capsules, solid pharmaceutical carriers are used.
  • Injectable preparations can be prepared using carriers such as distilled water, a salt solution, a glucose solution or a mixture of a salt solution and a glucose solution.
  • the preparations can be prepared in the form of a solution, suspension, or dispersion according to a conventional method using a suitable solubilizing agent and suspending agent.
  • Compounds (I) and pharmaceutically acceptable salts thereof can be administered orally in the said dosage forms or parenterally as injections.
  • the effective dose and the administration schedule vary depending upon the mode of administration, the age, body weight, and the condition of a patient, etc. Generally, however, Compounds (I) or pharmaceutically acceptable salts thereof are administered in a daily dose of 0.01 to 25 mg/kg in 3 to 4 parts.
  • Compounds (I) may also be administered by inhalation in the form of an aerosol, fine powders or a spray solution.
  • aerosol administration the compound of the present invention is dissolved in an appropriate pharmaceutically acceptable solvent such as ethyl alcohol or a combination of solvents containing ethyl alcohol, and the resulting solution is mixed with a pharmaceutically acceptable propellant.
  • Example 2 Substantially the same procedure as in Example 1 was repeated using 88 mg (0.221 mmol) of Compound b obtained in Reference Example 2. The obtained crude product was recrystallized from hexane/ethyl acetate to give 38 mg (39% yield) of Compound 3 as pale brown crystals.
  • Example 2 Substantially the same procedure as in Example 1 was repeated using 500 mg (1.255 mmol) of Compound e obtained in Reference Example 5. The obtained crude product was recrystallized from hexane/ethYl acetate to give 428 mg (77% yield) of Compound 4 as pale yellow crystals.
  • Example 2 Substantially the same procedure as in Example 1 was repeated using 305 mg (0.823 mmol) of Compound f obtained in Reference Example 6. The obtained crude product was recrystallized from hexane/ethyl acetate to give 214 mg (63% yield) of Compound 5 as white crystals.
  • Example 2 Substantially the same procedure as in Example 2 was repeated using 200 mg (0.502 mmol) of Compound e obtained in Reference Example 5. The obtained crude product was recrystallized from hexane/ethyl acetate to give 219 mg (87% yield) of Compound 6 as pale yellow crystals.
  • Example 2 Substantially the same procedure as in Example 2 was repeated using 200 mg (0.540 mmol) of Compound f obtained in Reference Example 6. The obtained crude product was recrystallized from hexane/ethyl acetate to give 170 mg (66% yield) of Compound 7 as yellow crystals.
  • Example 2 Substantially the same procedure as in Example 2 was repeated using 100 mg (0.294 mmol) of Compound g obtained in Reference Example 7. The obtained crude produck was recrystallized from ethyl acetate to give 108 mg (83% yield) of Compound 8 as yellow crystals.
  • Example 2 Substantially the same procedure as in Example 1 was repeated using 450 mg (1.171 mmol) of Compound h obtained in Reference Example 8. The obtained crude product was recrystallized from ethyl acetate to give 196 mg (36% yield) of Compound 9 as white crystals.
  • Example 2 Substantially the same procedure as in Example 1 was repeated using 1.00 g (2.70 mmol) of Compound f obtained in Reference Example 6, and 0.69 ml (5.38 mmol) of propionic anhydride in place of acetic anhydride. The obtained crude product was recrystallized from ethyl acetate to give 815 mg (71% yield) of Compound 12 as yellow crystals.
  • Example 2 Substantially the same procedure as in Example 2 was repeated using 1.00 g (2.70 mmol) of Compound f obtained in Reference Example 6, and 0.67 ml (5.44 mmol) of pivaloyl chloride in place of benzoyl chloride. The obtained crude product was recrystallized from ethyl acetate to give 722 mg (59% yield) of Compound 13 as pale yellow crystals.
  • Example 7 Substantially the same procedure as in Example 1 was repeated using 600 mg (1.76 mmol) of Compound g obtained in Reference Example 7. The obtained crude product was recrystallized from ethyl acetate to give 399 mg (59% yield) of Compound 14 as white crystals.
  • Example 2 Substantially the same procedure as in Example 1 was repeated using 800 mg (2.03 mmol) of Compound i obtained in Reference Example 9. The obtained crude product was recrystallized from toluene to give 830 mg (94% yield) of Compound 15 as white crystals.
  • Example 2 Substantially the same procedure as in Example 1 was repeated using 1.00 g (2.70 mmol) of Compound j obtained in Reference Example 10. The obtained crude product was recrystallized from ethyl acetate to give 807 mg (72% yield) of Compound 16 as pale yellow crystals.
  • Example 2 Substantially the same procedure as in Example 1 was repeated using 1.50 g (3.75 mmol) of Compound k obtained in Reference Example 11. The obtained crude product was recrystallized from ethanol/N, N-dimethylformamide to give 1.13 g (68% yield) of Compound 17 as yellow powders.
  • Example 2 Substantially the same procedure as in Example 2 was repeated using 1.50 g (3.75 mmol) of Compound k obtained in Reference Example 11. The obtained crude product was recrystallized from toluene/cyclohexane to give 1.16 g (61% yield) of Compound 18 as pale yellow crystals.
  • Example 2 Substantially the same procedure as in Example 1 was repeated using 1.19 g (2.81 mmol) of Compound m obtained in Reference Example 12. The obtained crude product was recrystallized from ethanol/N, N-dimethylformamide to give 680 mg (52% yield) of Compound 19 as white powders.
  • Example 2 Substantially the same procedure as in Example 2 was repeated using 1.00 g (2.36 mmol) of Compound m obtained in Reference Example 12. The obtained crude product was recrystallized from toluene/cyclohexane to give 990 mg (79% yield) of Compound 20 as white powders.
  • Example 13 Substantially the same procedure as in Example 1 was repeated using 3.00 g (8.81 mmol) of Compound n obtained in Reference Example 13. The obtained crude product was recrystallized from ethyl acetate to give 2.80 g (86% yield) of Compound 21 as white crystals.
  • Example 2 Substantially the same procedure as in Example 2 was repeated using 800 mg (2.23 mmol) of Compound n obtained in Reference Example 13. The obtained crude product was recrystallized from toluene/hexane to give 962 mg (97% yield) of Compound 22 as white powders.
  • Example 14 Substantially the same procedure as in Example 1 was repeated using 3.00 g (8.10 mmol) of Compound o obtained in Reference Example 14. The obtained crude product was recrystallized from ethyl acetate to give 3.25 g (97% yield) of Compound 23 as yellow crystals.
  • Example 2 Substantially the same procedure as in Example 2 was repeated using 800 mg (2.16 mmol) of Compound o obtained in Reference Example 14. The obtained crude product was recrystallized from N,N-dimethylformamide/water to give 972 mg (95% yield) of Compound 24 as yellow powders.
  • Example 15 Substantially the same procedure as in Example 1 was repeated using 2.00 g (5.40 mmol) of Compound p obtained in Reference Example 15. The obtained crude product was recrystallized from ethyl acetate to give 2.01 g (90% yield) of Compound 25 as white crystals.
  • Example 16 Substantially the same procedure as in Example 1 was repeated using 685 mg (1.92 mmol) of Compound q obtained in Reference Example 16. The obtained crude product was recrystallized from ethyl acetate to give 601 mg (71% yield) of Compound 26 as pale brown crystals.
  • Example 2 Substantially the same procedure as in Example 1 was repeated using 2.00 g (5.02 mmol) of Compound r obtained in Reference Example 17. The obtained crude product was purified by silica gel column chromatography to give 471 mg (22% yield) of Compound 27 as a yellow solid, which was recrystallized from dioxane/water to give yellow powders.
  • Tablets having the following composition are prepared according to a conventional method.
  • Fine granules having the following compositions are prepared according to a conventional method.
  • Capsules having the following composition are prepared according to a conventional method.
  • An injectable preparation having the following composition is prepared according to a conventional method.
  • Syrup having the following composition is prepared according to a conventional method.
  • the present invention provides novel xanthine derivatives and pharmaceutically acceptable salts thereof which are useful for treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A 2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).
  • diseases caused by hyperergasia of adenosine A 2 receptors for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof, represented by Formula (I): ##STR1## wherein R1, R2, and R3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl, R4 represents lower alkyl, or substituted or unsubstituted aryl, R5 and R6 independently represent hydrogen, lower alkyl, and lower alkoxy, or R5 and R6 are combined together to represent --O--(CH2)p--O-- (p is an integer of 1 to 3), n represents 0, 1, or 2, and m represents 1 or 2.
The compounds of the present invention have an adenosine A2 receptor antagonistic activity, and are useful for the treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).

Description

TECHNICAL FIELD
The present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof which have adenosine A2 receptor antagonistic activity and are useful for the treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).
BACKGROUND ART
It is known that adenosine exhibits neurotransmitter depressing activity Eur. J. Pharmacol., 168, 285 (1989)!, bronchospasmic activity Br. J. Pharmacol., 100, 251(1990)!, bone absorption promoting activity Acta Physiol. Scand., 131, 287(1987)!, and the like, via A2 receptors. Therefore, adenosine A2 receptor antagonists (hereinafter referred to as A2 -antagonists) are expected as therapeutic or preventive agents for various kinds of diseases caused by hyperergasia of adenosine A2 receptors, for example, therapeutic agents for Parkinson's disease, antidementia agents, antidepressants, anti-asthmatic agents, and therapeutic agents for osteoporosis. ##STR2##
It is known that adenosine antagonistic activity is found in compounds represented by Formula (A) in which R1a and R2a independently represent methyl or propyl, R3a represents hydrogen, and R4a represents substituted or unsubstituted phenyl, aromatic heterocyclic group, cycloalkyl, styryl, or phenylethyl J. Med. Chem., 34, 1431 (1991)!. Further, Japanese Published Examined Patent Application No. 26516/72 discloses, as cerebral stimulants, compounds represented by Formula (B) in which R1b and R2b independently represent methyl or ethyl, R3b represents methyl, y1b and y2b represent hydrogen, and Zb represents phenyl or 3,4,5-trimethoxyphenyl. WO92/06976 discloses, as compounds having an adenosine A2 receptor antagonistic activity and therapeutic effects on asthma and osteoporosis, compounds represented by Formula (B) in which R1b and R2b independently represent hydrogen, propyl, butyl, or allyl, R3b represents hydrogen or lower alkyl, y1b and y2b independently represent hydrogen or methyl, and Zb represents substituted or unsubstituted phenyl, pyridyl, imidazolyl, furyl, or thienyl. Further, it is known that adenosine A2 receptor antagonistic activity is found in compounds represented by Formula (B) in which R1b and R2b independently represent methyl, ethyl, propyl, or allyl, R3b represents hydrogen or methyl, y1b and y2b represent hydrogen, and Zb represents substituted or unsubstituted phenyl J. Med. Chem., 36, 1333 (1993)!. Furthermore, among compounds represented by Formula (B) in which R1b, R2b and R3b represent methyl, and y1b and y2b represent hydrogen, respectively, also known are a compound in which Zb represents phenyl (8-styryl caffeine) Chem. Ber. 119, 1525 (1986)!, and a compound in which Zb represents pyridyl, quinolyl, or methoxysubstituted or unsubstituted benzothiazolyl Chem. Abst. 60, 1741h (1964)!, although there is no description with regard to the pharmacological activity of any of these compounds.
DISCLOSURE OF THE INVENTION
The present invention relates to xanthine derivatives and pharmaceutically acceptable salts thereof represented by Formula (I): ##STR3## in which R1, R2, and R3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl, R4 represents lower alkyl, or substituted or unsubstituted aryl, R5 and R6 independently represent hydrogen, lower alkyl, and lower alkoxy, or R5 and R6 are combined together to represent --O--(CH2)p--O-- (p is an integer of 1 to 3), n represents 0,1, or 2, and m represents 1 or 2.
Hereinafter, the compounds represented by Formula (I) are referred to as Compounds (I). The same shall apply to the compounds represented by other Formulae.
In the definitions of the groups in Formula (I), lower alkyl and the alkyl moiety of lower alkoxy mean straight-chain or branched alkyl group having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl and hexyl; lower alkenyl means straight-chain or branched alkenyl group having 2-6 carbon atoms such as vinyl, allyl, methacryl, crotyl, 3-butenyl, 2-pentenyl, 4-pentenyl, 2-hexenyl and 5-hexenyl; lower alkynyl means a straight-chain or branched alkynyl group having 2 to 6 carbon atoms such as ethynyl, propargyl, 2-butynyl, 3-butynyl, 2-pentynyl, 4-pentynyl, 2-hexynyl, 5-hexynyl and 4-methyl-2 pentynyl; and aryl represents phenyl or naphtyl.
Each of the substituents for aryl has 1 to 4 substitutions, and examples of which are substituted or unsubstituted lower alkyl, hydroxy, substituted or unsubstituted lower alkoxy, halogen, nitro, amino, lower alkylamino, di-lower alkylamino, benzyloxy, phenyl, and phenoxy. The lower alkyl, and the alkyl moiety of lower alkoxy, lower alkylamino and di-lower alkylamino have the same meanings as the lower alkyl defined above, and the halogen represents an atom of fluorine, chlorine, bromine, or iodine. Each of the substituents for lower alkyl and lower alkoxy has 1 to 3 substitutions, and examples of which are halogen, nitro, lower alkoxy and amino, wherein halogen and lower alkoxy have the same meanings as defined above.
The pharmaceutically acceptable salts of Compounds (I) include pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts and amino acid addition salts.
The pharmaceutically acceptable acid addition salts include inorganic salts such as hydrochloride, sulfate, and phosphate, and organic salts such as acetate, maleate, fumarate, tartrate and citrate. The pharmaceutically acceptable metal salts include alkaline metal salts such as sodium salt and potassium salt, and alkali earth metal salts such as magnesium salt and calcium salt, aluminium salt, and zinc salt. The pharmaceutically acceptable ammonium salts include salts of ammonium and tetramethyl ammonium. The pharmaceutically acceptable organic amine addition salts include salts with morphorine and piperidine. The pharmaceutically acceptable amino acid addition salts include salts with lysine, glycine and phenylalanine.
A process for producing Compounds (I) is described below.
Compounds (I) are prepared according to the following reaction steps. ##STR4## (wherein, R1, R2, R3, R4, R5, R6, n, and m have the same meanings as defined above, R7 represents the lower alkyl as defined above, or methoxymethyl, X represents an atom of chlorine, bromine, or iodine, and na represents 1 or 2.)
Step 1:
Compounds (III) can be prepared by dealkylation of Compounds (II) obtained by known methods (e.g., WO92/06976). Examples of preferable dealkylation agent are boron tribromide and its dimethyldisulfide complex, boron trichloride, iodotrimethylsilane, sodium ethanethiolate, sodium benzenthiolate, gas of hydrogen chloride, hydrochloric acid and hydrobromic acid. The reaction solvent, varying depending on the dealkylation agent employed, is selected from aromatic hydrocarbons such as toluene and xylene, halogenohydrocarbons such as methylene chloride, chloroform and ethane dichloride, ethers such as dioxane and tetrahydrofuran, alcohols such as methanol and ethanol, dimethylformamide and acetic acid. The reaction is carried out at -30° to 140° C., and is completed in 10 minutes to 120 hours.
Step 2:
(Method A)
Compounds (I) wherein n is 0 can be obtained by reacting Compounds (III) with carboxylic acid (IV) or its reactive derivatives.
The reactive derivatives of Compounds (IV) include acid halides such as acid chloride and acid bromide, activated esters such as p-nitrophenyl ester and N-oxysuccinimide, acid anhydrides which are commercially available or which are produced using carbodiimide such as 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide, diisopropylcarbodiimide and dicyclohexylcarbodiimide, and mixed acid anhydrides with monoethyl carbonate, monoisobutyl carbonate.
Generally, in case of using Compounds (IV), the reaction is carried out at 50° to 200° C. in the absence of solvent, and completed in 10 minutes to 5 hours.
When the reactive derivatives of Compounds (IV) are used in this step, the reaction can be carried out according to a method conventionally used in peptide chemistry. That is, Compounds (I), wherein n is 0, can be obtained by reacting Compounds (III) with the reactive derivatives of Compounds (IV) preferably in the presence of an additive or base. The reaction solvent is suitably selected from halogenohydrocarbons such as methylene chloride, chloroform and ethane dichloride, ethers such as dioxane and tetrahydrofuran, dimethylformamide, dimethylsulfoxide, water, etc. The additive includes 1-hydroxybenzotriazole. Pyridine, triethylamine, 4-dimethylaminopyridine, N-methylmorphorine, etc., are used as the base. The reaction is carried out at -80° to 50° C., and is completed in 0.5 to 24 hours. The reactive derivative, which is produced in the reaction system, may be used without isolation.
(Method B)
Compounds (I) wherein n is 1 or 2 can be obtained by reacting Compounds (III) with alkylation agent (V) in the presence of a base, if necessary.
The base includes alkaline metal carbonates such as sodium carbonate and potassium carbonate, alkaline metal hydrides such as sodium hydride, and alkaline metal alkoxides such as sodium methoxide and sodium ethoxide. As a reaction solvent, aromatic hydrocarbons such as toluene and xylene, ketones such as acetone and methylethylketone, dimethylformamide, dimethylsulfoxide, etc., are used. The reaction is carried out at 0° to 180° C. and is completed in 0.5 to 24 hours.
The desired compounds prepared according to the process described above can be isolated and purified by purification methods conventionally used in organic synthetic chemistry such as filtration, extraction, washing, drying, concentration, recrystallization and various kinds of chromatographies.
In the case where a salt of Compound (I) is desired and it is produced in the form of the desired salt, it can be subjected to purification as such. In the case where Compound (I) is produced in the free state and its salt is desired, Compound (I) is dissolved or suspended in a suitable solvent, followed by addition of an acid or a base to form a salt.
Compounds (I) can exist in the form of geometrical isomers such as an (E)-isomer and a (Z)-isomer, and the present invention covers all possible isomers including these geometrical isomers and mixtures thereof. In the case where separation between an (E)-isomer and a (Z)-isomer is desired, they can be isolated and purified by fractionation methods, for example, fractional crystallization, fractional precipitation, fractional dissolution, and various kinds of chromatographies.
Compounds (I) and pharmaceutically acceptable salts thereof may exist in the form of an adduct with water or various kinds of solvents, which are also within the scope of the present invention.
Specific examples of Compounds (I) are shown in Table 1.
                                  TABLE 1                                 
__________________________________________________________________________
 ##STR5##                                                                 
Compound                                                                  
       R.sup.1 R.sup.2 Z                                                  
__________________________________________________________________________
 1     (CH.sub.2).sub.2 CH.sub.3                                          
               (CH.sub.2).sub.2 CH.sub.3                                  
                        ##STR6##                                          
 2     (CH.sub.2).sub.2 CH.sub.3                                          
               (CH.sub.2).sub.2 CH.sub.3                                  
                        ##STR7##                                          
 3     (CH.sub.2).sub.2 CH.sub.3                                          
               (CH.sub.2).sub.2 CH.sub.3                                  
                        ##STR8##                                          
 4     (CH.sub.2).sub.2 CH.sub.3                                          
               (CH.sub.2).sub.2 CH.sub.3                                  
                        ##STR9##                                          
 5     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR10##                                         
 6     (CH.sub.2).sub.2 CH.sub.3                                          
               (CH.sub.2).sub.2 CH.sub.3                                  
                        ##STR11##                                         
 7     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR12##                                         
 8     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR13##                                         
 9     (CH.sub.2).sub.2 CH.sub.3                                          
               (CH.sub.2).sub.2 CH.sub.3                                  
                        ##STR14##                                         
10     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR15##                                         
11     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR16##                                         
12     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR17##                                         
13     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR18##                                         
14     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR19##                                         
15     CH.sub.2 CHCH.sub.2                                                
               CH.sub.2 CHCH.sub.2                                        
                        ##STR20##                                         
16     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR21##                                         
17     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR22##                                         
18     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR23##                                         
19     CH.sub.2 CHCH.sub.2                                                
               CH.sub.2 CHCH.sub.2                                        
                        ##STR24##                                         
20     CH.sub.2 CHCH.sub.2                                                
               CH.sub.2 CHCH.sub.2                                        
                        ##STR25##                                         
21     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR26##                                         
22     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR27##                                         
23     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR28##                                         
24     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR29##                                         
25     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR30##                                         
26     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR31##                                         
27     CH.sub.2 CH.sub.3                                                  
               CH.sub.2 CH.sub.3                                          
                        ##STR32##                                         
__________________________________________________________________________
The pharmacological activities of Compounds (I) are shown below by test examples.
TEST EXAMPLE 1 Adenosine Receptor Antagonistic Activity (Adenosine A2 Receptor Binding Test)
The test was conducted according to the method of Bruns et al. Mol. Pharmacol., 29, 331 (1986)! with slight modification.
Corpus striatum of a rat was suspended in ice-cooled 50 mM Tris (hydroxymethyl) aminomethane hydrochloride (Tris HCl) buffer (pH 7.7) by using Polytron homogenizer (manufactured by Kinematica Co.). The suspension was centrifuged (50,000×g, 10 minutes), and the precipitate was suspended again in the same amount of 50 mM Tris HCl buffer. The suspension was centrifuged under the same conditions, and the final precipitate was suspended in 50 mM Tris HCl buffer containing 10 mM magnesium chloride and 0.02 unit/mg tissue of adenosine deaminase (manufactured by Sigma Co.)! to give a tissue concentration of 5 mg (wet weight)/ml.
To 1 ml of the tissue suspension thus prepared were added 50 μl of tritium labeled CGS 21680 {3 H-2- p-(2-carboxyethyl) phenethylamino!-5'-(N-ethylcarboxamide)-adenosine: 40 Ci/mmol; manufactured by New England Nuclear Co. J. Pharmacol. Exp. Ther., 251, 888 (1989)!} (final concentration: 4.0 nM) and 50 μl of a test compound. The resulting mixture was allowed to stand at 25° C. for 120 minutes and then rapidly filtered by suction through a glass fiber filter (GF/C; manufactured by Whatman Co.). The filter was immediately washed three times with 5 ml each of ice-cooled 50 mM Tris HCl buffer, and transferred to a vial, and a scintillator (EX-H; manufactured by Wako Pure Chemical Industries, Ltd.) was added thereto. The radioactivity on the filter was determined with a liquid scintillation counter (manufactured by Packard Instrument Co.).
The inhibition rate of the test compound against the binding of A2 receptors (3 H-CGS 21680 binding) was calculated by the following equation: ##EQU1## Notes!B: Amount of the binding in the presence of the test compound.
T: Amount of the total binding.
N: Amount of the nonspecific binding.
Amount of the total binding means the amount of radioactivity of 3 H-CGS 21680 bound in the absence of the test compound. Amount of the nonspecific binding means the amount of radioactivity of 3 H-CGS 21680 bound in the presence of 100 μM cyclopentyladenosine (CPA; manufactured by Sigma Co.). Amount of the binding in the presence of the test compound means the amount of radioactivity of 3 H-CGS 21680 bound in the presence of the test compound at various levels of concentrations.
The results are shown in Table 2.
              TABLE 2                                                     
______________________________________                                    
              A.sub.2 Receptor                                            
              Inhibition Rate (%)                                         
Compd.          10.sup.-7 M                                               
                        10.sup.-6 M                                       
______________________________________                                    
 1              89      93                                                
 3              61      96                                                
 4              94      98                                                
 5              91      100                                               
 6              81      96                                                
 7              87      97                                                
 9              88      96                                                
12              86      96                                                
14              86      93                                                
15              85      91                                                
16              81      96                                                
17              80      97                                                
18              82      97                                                
19              91      96                                                
21              81      96                                                
22              92      99                                                
23              90      101                                               
25              95      101                                               
26              75      101                                               
______________________________________
Compounds (I) and pharmaceutically acceptable salts thereof exhibit a potent adenosine A2 receptor antagonistic activity. Thus, they are effective against various kinds of diseases caused by hyperergasia of adenosine A2 receptors (for example, Parkinson's disease, senile dementia, asthma, and osteoporosis).
TEST EXAMPLE 2 Effect on Haloperidol-Induced Catalepsy
Parkinson's disease is a clinical syndrome caused by degeneration and cell death of nigrostriatal dopaminergic neurons. Administration of haloperidol (dopamine D1 /D2 antagonist) induces catalepsy resulting from the blockade of postsynaptic dopamine D2 receptors. It is generally accepted that this haloperidol-induced catalepsy is a classical model to reproduce drug-induced Parkinson's disease Eur. J. Pharmacol., 182, 327 (1990).
The experiment was carried out using several groups of 5-week-old male ddY mice (weighing 22 to 24 g, Japan SLC), each group consisting of 5 or 10 mice. Haloperidol (manufactured by Janssen Pharmaceutica) was suspended in 0.3% CMC and imtraperitoneally administered to each mouse at a dose of 1.0 mg/kg. A test compound was suspended in injectable distilled water (manufactured by Otsuka Pharmaceutical Co., Ltd.) after adding Tween 80 polyoxyethylene (20) sorbitan monooleate!. L-DOPA (manufactured by Kyowa Hakko Kogyo Co., Ltd.) and benserazide hydrochloride (manufactured by Kyowa Hakko Kogyo Co., Ltd.) were suspended in 0.3% CMC. One hour after the intraperitoneal administration of haloperidol, the suspension containing the test compound or the suspension containing no test compound injectable distilled water (manufactured by Otsuka Pharmaceutical Co., Ltd.) containing Tween 80; control! were orally administered to the separate groups of the mice (0.1 ml per 10 g of body weight). One hour after the administration of the test compound, the forelimbs of each mouse and subsequently the hindlimbs of the same mouse were placed on a 4.5 cm-high, 1.0 cm-wide bar and catalepsy was estimated. All of the test compounds were orally administered at a dose of 10 mg/kg, and L-DOPA (100 mg/kg) and benserazide (25 mg/kg) were intraperitoneally administered together as a control. The catalepsy score and the standard of judgment are shown below.
______________________________________                                    
Score      Duration of the category                                       
______________________________________                                    
0:             forelimbs   less than 5 seconds                            
               hindlimbs   less than 5 seconds                            
1:             forelimbs   from 5 (inclusive)                             
                           to 10 (exclusive) seconds                      
               hindlimbs   less than 5 seconds                            
2:             forelimbs   10 seconds or more                             
               hindlimbs   less than 5 seconds                            
3:      (1)    forelimbs   from 5 (inclusive)                             
                           to 10 (exclusive) seconds                      
               hindlimbs   from 5 (inclusive)                             
                           to 10 (exclusive) seconds                      
        or (2) forelimbs   less than 5 seconds                            
               hindlimbs   5 seconds or more                              
4:      (1)    forelimbs   10 seconds or more                             
               hindlimbs   from 5 (inclusive)                             
                           to 10 (exclusive) seconds                      
        or (2) forelimbs   from 5 (inclusive)                             
                           to 10 (exclusive) seconds                      
               hindlimbs   10 seconds or more                             
5:             forelimbs   10 seconds or more                             
               hindlimbs   10 seconds or more                             
______________________________________
The effect of the compounds was evaluated by the total of the catalepsy scores of 5 or 10 mice in each group (25 or 50 points at the maximum). The groups wherein the total score was not more than 20 or 40 points were estimated to be effective. The number of the animals showing remission against catalepsy is the number of the mice for which the catalepsy score was not more than 4 points in 5 or 10 mice. The remission rate against catalepsy shows the rate of decrease in the total score based on that of the control group.
The results are shown in Table 3.
              TABLE 3                                                     
______________________________________                                    
           Number of                                                      
                    Total  Number of Animals                              
                                      Remission                           
Compound   Animals  Score  Showing Remission                              
                                      Rate (%)                            
______________________________________                                    
0.3% Tween 80                                                             
           5        25     0           0                                  
(Control)                                                                 
L-DOPA +   5        18     4          28                                  
benserazide                                                               
 4         5         3     5          88                                  
 5         5         2     5          92                                  
 6         5         9     5          64                                  
 7         5        14     3          44                                  
12         10       10     10         80                                  
13         10       14     9          72                                  
14         10       11     10         78                                  
17         10       30     7          40                                  
18         10       30     7          40                                  
______________________________________
TEST EXAMPLE 3 Effect on Clonidine-Induced Aggressive Behavior
The enhancement effect of the test compounds on the aggressive behavior induced by intraperitoneal administration of clonidine Eur. J. Pharmacol., 29, 374 (1968)! was investigated.
The experiment was performed using several groups of male ddY mice weighing 20 to 25 g (Japan SLC), each group consisting of two mice. A test compound was suspended in injectable distilled water (manufactured by Otsuka Pharmaceutical Co., Ltd.) after adding Tween 80. Clonidine hydrochloride (manufactured by Sigma Co.) was dissolved in physiological saline solution (manufactured by Otsuka Pharmaceutical Co., Ltd.). The suspension containing the test compound and the suspension containing no test compound (control) were orally administered to the separate groups of the mice (0.1 ml per 10 g of body weight). Sixty minutes after the oral administration of the test compound, clonidine hydrochloride (20 mg/kg) was intraperitoneally administered. The number of biting attacks during the 30 minutes immediately after the clonidine treatment was counted. The effect of the compounds was evaluated by comparing the number of biting attacks of the test compound-administered groups with that of control groups (significance test: Student' t-test).
The results are shown in Table 4.
              TABLE 4                                                     
______________________________________                                    
        Number of the Biting Attacks                                      
        (mean ± S.E.M.)                                                
                         Test Compound-                                   
                                   Ratio of Attacks:                      
      Dose    Control Group                                               
                         Treated Group                                    
                                   Test Compd.-                           
      (mg/kg, (Number of (Number of                                       
                                   Treated Group/                         
Compd.                                                                    
      po)     Animals)   Animals)  Control Group                          
______________________________________                                    
 4    2.5     4.3 ± 1.9                                                
                          47.4 ± 11.1**                                
                                   11.0                                   
              (15)       (15)                                             
 5    0.63    3.9 ± 1.5                                                
                         19.1 ± 6.6*                                   
                                   4.9                                    
              (15)       (15)                                             
 6    10      2.3 ± 1.3                                                
                          36.8 ± 10.8**                                
                                   16.0                                   
              (15)       (15)                                             
12    2.5     1.9 ± 1.3                                                
                          38.5 ± 8.4**                                 
                                   20.3                                   
              (10)       (10)                                             
13    2.5     2.4 ± 1.1                                                
                          24.3 ± 6.6**                                 
                                   10.1                                   
              (10)       (10)                                             
14    0.63    5.2 ± 1.6                                                
                         21.4 ± 7.4*                                   
                                   4.1                                    
              (15)       (15)                                             
______________________________________                                    
 *p <0.05; **p <0.01
Compounds (I) and pharmaceutically acceptable salts thereof can be administered as they are, or in the form of various pharmaceutical compositions. The pharmaceutical compositions in accordance with the present invention can be prepared by uniformly mixing an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, as an active ingredient, with pharmaceutically acceptable carriers. It is desired that such pharmaceutical compositions are prepared in a unit dose form suitable for oral administration or administration through injection.
For preparing a pharmaceutical composition for oral administration, any useful pharmaceutically acceptable carrier may be used. For example, liquid preparations for oral administration such as a suspension and syrup can be prepared using water, sugars such as sucrose, sorbitol and fructose, gycols such as polyethylene glycol and propylene glycol, oils such as sesame oil, olive oil and soybean oil, preservatives such as p-hydroxybenzoates, flavors such as strawberry flavor and peppermint, and the like. Powders, pills, capsules, and tablets can be prepared using excipients such as lactose, glucose, sucrose, and mannitol, disintegrating agents such as starch and sodium alginate, lubricants such as magnesium stearate and talc, binders such as polyvinyl alcohol, hydroxypropyl cellulose, and gelatin, surfactants such as fatty acid esters, plasticizers such as glycerin, and the like. Tablets and capsules are the most useful oral unit dose forms because of the readiness of administration. For preparing tablets and capsules, solid pharmaceutical carriers are used.
Injectable preparations can be prepared using carriers such as distilled water, a salt solution, a glucose solution or a mixture of a salt solution and a glucose solution. The preparations can be prepared in the form of a solution, suspension, or dispersion according to a conventional method using a suitable solubilizing agent and suspending agent.
Compounds (I) and pharmaceutically acceptable salts thereof can be administered orally in the said dosage forms or parenterally as injections. The effective dose and the administration schedule vary depending upon the mode of administration, the age, body weight, and the condition of a patient, etc. Generally, however, Compounds (I) or pharmaceutically acceptable salts thereof are administered in a daily dose of 0.01 to 25 mg/kg in 3 to 4 parts.
In addition, Compounds (I) may also be administered by inhalation in the form of an aerosol, fine powders or a spray solution. In the case of aerosol administration, the compound of the present invention is dissolved in an appropriate pharmaceutically acceptable solvent such as ethyl alcohol or a combination of solvents containing ethyl alcohol, and the resulting solution is mixed with a pharmaceutically acceptable propellant.
Certain embodiments of the present invention are illustrated in the following examples, reference examples, and preparation examples.
EXAMPLE 1 (E)-8-(3,4-Diacetoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 1)
Compound a (350 mg, 0.910 mmol) obtained in Reference Example 1 was dissolved in 7 ml of pyridine, and acetic anhydride (0.51 ml, 5.405 mmol) was added thereto, followed by stirring at room temperature for 5 hours. Water was added to the reaction mixture, and the resulting precipitate was collected by filtration. The obtained crude product was recrystallized from hexane/ethyl acetate to give 294 mg (69% yield) of Compound 1 as pale yellow crystals.
Melting Point:229.4°-230.2° C. Elemental Analysis:C24 H28 N4 O6 Calcd. (%):C 61.53, H 6.02, N 11.96 Found (%):C 61.56, H 6.05, N 11.97 IR(KBr)νmax (cm-1):1697, 1657, 1509, 1214. NMR (270 MHz; CDCl3) δ(ppm):7.73(1H, d, J=15.5 Hz), 7.47-7.43(2H, m), 7.24(1H, d, J=8.3 Hz), 6.84(1H, d, J=15.5 Hz), 4.08(2H, t, J=7.6 Hz), 4.05(3H, s), 3.98(2H, q, J=7.6 Hz), 2.32(3H, s), 2.31(3H, s), 1.83(2H, m), 1.69(2H, m), 1.00(3H, t, J=7.6 Hz), 0.97(3H, t, J=7.6 Hz).
EXAMPLE 2 (E)-8-(3,4-Dibenzoyloxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 2)
Compound a (500 mg, 1.301 mmol) obtained in Reference Example 1 was dissolved in 10 ml of pyridine, and benzoyl chloride (0.60 ml, 5.169 mmol) was added thereto under ice-cooling, followed by stirring at room temperature for 3.5 hours. Ice and water were added to the reaction mixture, and the resulting precipitate was collected by filtration. The obtained crude product was recrystallized from ethyl acetate to give 663 mg (86% yield) of Compound 2 as white crystals.
Melting Point:230.8°-231.1° C. Elemental Analysis:C34 H32 N4 O6.0.2 H2 O Calcd. (%):C 68.49, H 5.48, N 9.40 Found (%):C 68.50, H 5.40, N 9.35 IR(KBr)νmax (cm-1):1747, 1694, 1654, 1440, 1242. NMR (270 MHz; CDCl3) δ(ppm):8.10-8.05(4H, m), 7.81(1H, d, J=15.5 Hz), 7.76-7.36(9H, m), 6.91(1H, d, J=15.5 Hz), 4.14-3.96(4H, m), 4.07(3H, s), 1.91-1.63(4H, m), 1.01(3H, t, J=7.6 Hz), 0.97(3H, t, J=7.6 Hz).
EXAMPLE 3 (E)-8-(3-Acetoxy-4-methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 3)
Substantially the same procedure as in Example 1 was repeated using 88 mg (0.221 mmol) of Compound b obtained in Reference Example 2. The obtained crude product was recrystallized from hexane/ethyl acetate to give 38 mg (39% yield) of Compound 3 as pale brown crystals.
Melting Point:200.8°-201.8° C. Elemental Analysis:C23 H28 N4 O5 Calcd. (%):C 62.72, H 6.40, N 12.72 Found (%):C 62.41, H 6.50, N 12.52 IR(KBr)νmax (Cm-1):1699, 1655, 1516, 1439, 1273. NMR (270 MHz; CDCl3) δ(ppm):7.70(1H, d, J=15.8 Hz), 7.41(1H, dd, J=8.6, 2.0 Hz), 7.32(1H, d, J=2.0 Hz), 6.98(1H, d, J=8.6 Hz), 6.75(1H, d, J=15.8 Hz), 4.12-3.95(4H, m), 4.04(3H, s), 3.88(3H, s), 2.34(3H, s), 1.90-1.65(4H, m), 1.00(3H, t, J=7.3 Hz), 0.96(3H, t, J=7.3 Hz)
EXAMPLE 4 (E)-8-(4-Acetoxy-3-methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 4)
Substantially the same procedure as in Example 1 was repeated using 500 mg (1.255 mmol) of Compound e obtained in Reference Example 5. The obtained crude product was recrystallized from hexane/ethYl acetate to give 428 mg (77% yield) of Compound 4 as pale yellow crystals.
Melting Point:179.4°-181.3° C. Elemental Analysis:C23 H28 N4 O5 Calcd. (%):C 62.72, H 6.40, N 12.72 Found (%):C 62.51, H 6.43, N 12.98 IR(KBr)νmax (cm-1):1759, 1692, 1660, 1542, 1509, 1438. NMR (270 MHz; CDCl3) δ(ppm):7.75(1H, d, J=15.8 Hz), 7.20(1H, dd, J=8.2, 1.7 Hz), 7.13(1H, d, J=1.7 Hz), 7.08(1H, d, J=8.2 Hz), 6.84(1H, d, J=15.8 Hz), 4.13-3.95(4H, m), 4.07(3H, s), 3.90(3H, s), 2.34(3H, s), 1.91-1.62(4H, m), 1.01(3H, t, J=7.6 Hz), 0.97(3H, t, J=7.6 Hz)
EXAMPLE 5 (E)-8-(4-Acetoxy-3-methoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 5)
Substantially the same procedure as in Example 1 was repeated using 305 mg (0.823 mmol) of Compound f obtained in Reference Example 6. The obtained crude product was recrystallized from hexane/ethyl acetate to give 214 mg (63% yield) of Compound 5 as white crystals.
Melting Point:193.8°-194.6° C. Elemental Analysis:C21 H24 N4 O5 Calcd. (%):C 61.16, H 5.86, N 13.58 Found (%):C 61.21, H 5.89, N 13.70 IR(KBr)νmax (cm-1):1754, 1694, 1658, 1512, 1440. NMR (270 MHz; CDCl3) δ(ppm):7.76(1H, d, J=15.8 Hz), 7.20(1H, dd, J=8.2, 2.0 Hz), 7.13(1H, d, J=2.0 Hz), 7.08(1H, d, J=8.2 Hz), 6.85(1H, d, J=15.8 Hz), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.07(3H, s), 3.90(3H, s), 2.34(3H, s), 1.39(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz).
EXAMPLE 6 (E)-8-(4-Benzoyloxy-3-methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 6)
Substantially the same procedure as in Example 2 was repeated using 200 mg (0.502 mmol) of Compound e obtained in Reference Example 5. The obtained crude product was recrystallized from hexane/ethyl acetate to give 219 mg (87% yield) of Compound 6 as pale yellow crystals.
Melting Point:156.1°-157.4° C. Elemental Analysis:C28 H30 N4 O5 Calcd. (%):C 66.92, H 6.01, N 11.15 Found (%):C 66.87, H 5.84, N 11.11 IR(KBr)νmax (cm-1):1731, 1693, 1649, 1540, 1509, 1437, 1251. NMR (270 MHz; CDCl3) δ(ppm):8.24-8.21(2H, m), 7.78(1H, d, J=15.8 Hz), 7.68-7.50(3H, m), 7.27-7.18(3H, m), 6.88(1H, m), 4.14-3.96(4H, m), 4.08(3H, s), 3.89(3H, s), 1.89-1.66(4H, m), 1.01(3H, t, J=7.6 Hz), 0.97(3H, t, J=7.6 Hz).
EXAMPLE 7 (E)-8-(4-Benzoyloxy-3-methoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 7)
Substantially the same procedure as in Example 2 was repeated using 200 mg (0.540 mmol) of Compound f obtained in Reference Example 6. The obtained crude product was recrystallized from hexane/ethyl acetate to give 170 mg (66% yield) of Compound 7 as yellow crystals.
Melting Point:234.3°-235.6° C. Elemental Analysis:C26 H26 N4 O5 Calcd. (%):C 65.81, H 5.52, N 11.81 Found (%):C 65.52, H 5.58, N 11.79 IR(KBr) νmax (cm-1):1735, 1694, 1652, 1540, 1509, 1436, 1253. NMR (270 MHz; CDCl3) δ(ppm):8.24-8.21(2H, m), 7.79(1H, d, J=15.8 Hz), 7.68-7.50(3H, m), 7.28-7.19(3H, m), 6.88(1H, m), 4.22(2H, q, J=6.9 Hz), 4.10(2H, q, J=6.9 Hz), 4.08(3H, s), 3.89(3H, s), 1.39(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz).
EXAMPLE 8 (E)-8-(4-Benzoyloxystyryl)-1,3-diethyl-7-methylxanthine (Compound 8)
Substantially the same procedure as in Example 2 was repeated using 100 mg (0.294 mmol) of Compound g obtained in Reference Example 7. The obtained crude produck was recrystallized from ethyl acetate to give 108 mg (83% yield) of Compound 8 as yellow crystals.
Melting Point:208.4°-209.3° C. Elemental Analysis:C25 H24 N4 O4 Calcd. (%):C 67.56, H 5.44, N 12.61 Found (%):C 67.46, H 5.40, N 12.53 IR(KBr) νmax (cm-1):1693, 1655, 1510, 1265, 1215. NMR (270 MHz; CDCl3) δ(ppm):8.22(2H, d, J=7.3 Hz), 7.81(1H, d, J=15.8 Hz), 7.67-7.50(5H, m), 7.29(2H, d, J=8.6 Hz), 6.90(1H, d, J=15.8 Hz), 4.32(2H, q, J=6.9 Hz), 4.10(2H, q, J=6.9 Hz), 4.07(3H, s), 1.39(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz).
EXAMPLE 9 (E)-8-(3,5-Diacetoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound 9)
Substantially the same procedure as in Example 1 was repeated using 450 mg (1.171 mmol) of Compound h obtained in Reference Example 8. The obtained crude product was recrystallized from ethyl acetate to give 196 mg (36% yield) of Compound 9 as white crystals.
Melting Point:224.3°-225.1° C. Elemental Analysis:C24 H28 N4 O6 Calcd. (%):C 61.53, H 6.02, N 11.96 Found (%):C 61.75, H 6.15, N 12.10 IR(KBr) νmax (cm-1):1761, 1695, 1655, 1540, 1197. NMR (270 MHz; CDCl3) δ(ppm):7.73(1H, d, J=15.8 Hz), 7.21(2H, d, J=2.0 Hz), 6.92(1H, t, J=2.0 Hz), 6.88(1H, d, J=15.8 Hz), 4.12-3.95(4H, m), 4.06(3H, s), 2.32(6H, s), 1.89-1.62(4H, m), 1.00(3H, t, J=7.6 Hz), 0.97(3H, t, J=7.6 Hz).
EXAMPLE 10 (E)-8-(4-Acetonyloxy-3-methoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 10)
Compound f (200 mg, 0.540 mmol) obtained in Reference Example 6 was dissolved in 4 ml of dimethylformamide, and potassium carbonate (374 mg, 2.706 mmol) and bromoacetone (0.2 ml, 2.142 mmol) were added thereto, followed by stirring at room temperature for 7 hours. Water was added to the reaction mixture, and the resulting precipitate was collected by filtration. The obtained crude product was dissolved in chloroform, and the solution was washed with saturated aqueous sodium chloride three times, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation, and the residue was recrystallized from ethyl acetate to give 172 mg (75% yield) of Compound 10 as pale yellow crystals.
Melting Point:205.7°-206.1° C. Elemental Analysis:C22 H26 N4 O5 Calcd. (%):C 61.96, H 6.14, N 13.14 Found (%):C 61.97, H 6.30, N 12.98 IR(KBr) νmax (c-1):1694, 1660, 1515, 1262. NMR (270 MHz; CDCl3) δ(ppm):7.73(1H, d, J=15.8 Hz), 7.23-7.12(2H, m), 6.78(1H, d, J=15.8 Hz), 6.77(1H, d, J=8.6 Hz), 4.64(2H, s), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.07(3H, s), 3.96(3H, s), 2.30(3H, s), 1.38(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz).
EXAMPLE 11 (E)-1,3-Diethyl-8-(3-methoxy-4-phenacyloxystyryl)-7-methylxanthine (Compound 11)
Compound f (200 mg, 0.540 mmol) obtained in Reference Example 6 was dissolved in 4 ml of dimethylformamide, and potassium carbonate (149 mg, 1.078 mmol) and bromoacetophenone (161 mg, 0.809 mmol) were added thereto, followed by stirring at room temperature overnight. Water was added to the reaction mixture, and the resulting precipitate was collected by filtration. The obtained crude product was dissolved in chloroform, and the solution was washed with saturated aqueous sodium chloride three times, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation, and the residue was recrystallized from ethyl acetate to give 177 mg (67% yield) of Compound 11 as pale yellow crystals.
Melting Point:180.4°-182.1° C. Elemental Analysis:C27 H28 N4 O5 Calcd. (%):C 66.38, H 5.77, N 11.47 Found (%):C 66.18, H 5.81, N 11.37 IR(KBr) νmax (cm-1):1688, 1656, 1516, 1256. NMR (270 MHz; CDCl3) δ(ppm):8.03-8.00(2H, m), 7.72(1H, d, J=15.8 Hz), 7.66-7.48(3H, m), 7.12-7.10(2H, m), 6.84-6.81(1H, m), 6.76(1H, d, J=15.8 Hz), 5.41(2H, s), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.05(3H, s), 3.96(3H, s), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz).
EXAMPLE 12 (E)-1,3-Diethyl-8-(3-methoxy-4-propionyloxystyryl)-7-methylxanthine (Compound 12)
Substantially the same procedure as in Example 1 was repeated using 1.00 g (2.70 mmol) of Compound f obtained in Reference Example 6, and 0.69 ml (5.38 mmol) of propionic anhydride in place of acetic anhydride. The obtained crude product was recrystallized from ethyl acetate to give 815 mg (71% yield) of Compound 12 as yellow crystals.
Melting Point:183.6°-183.9° C. Elemental Analysis:C22 H26 N4 O5 Calcd. (%):C 61.96, H 6.14, N 13.14 Found (%):C 61.86, H 6.15, N 13.10 IR(KBr) νmax (cm-1):1764, 1691, 1654, 1542, 1510, 1435. NMR (270 MHz; CDCl3) δ(ppm):7.76(1H, d, J=15.5 Hz), 7.20(1H, d, J=7.9 Hz), 7.13(1H, s), 7.07(1H, d, J=7.9 Hz), 6.85(1H, d, J=15.5 Hz), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.07(3H, s), 3.89(3H, s), 2.64(2H, q, J=7.6 Hz), 1.39(3H, t, J=6.9 Hz), 1.29(3H, t, J=7.6 Hz), 1.27(3H, t, J=6.9 Hz).
EXAMPLE 13 (E)-1,3-Diethyl-8-(3-methoxy-4-pivaloyloxystyryl)-7-methylxanthine (Compound 13)
Substantially the same procedure as in Example 2 was repeated using 1.00 g (2.70 mmol) of Compound f obtained in Reference Example 6, and 0.67 ml (5.44 mmol) of pivaloyl chloride in place of benzoyl chloride. The obtained crude product was recrystallized from ethyl acetate to give 722 mg (59% yield) of Compound 13 as pale yellow crystals.
Melting Point:207.7°-208.3° C. Elemental Analysis:C24 H30 N4 O5 Calcd. (%):C 63.42, H 6.65, N 12.33 Found (%):C 63.44, H 6.66, N 12.31 IR(KBr) νmax (cm-1):1756, 1694, 1658, 1437, 1108. NMR (270 MHz; CDCl3) δ(ppm):7.76(1H, d, J=15.5 Hz), 7.20(1H, dd, J=7.9, 1.7 Hz), 7.12(1H, d, J=1.7 Hz), 7.04(1H, d, J=7.9 Hz), 6.85(1H, d, J=15.5 Hz), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.07(3H, s), 3.88(3H, s), 1.39(3H, t, J=6.9 Hz), 1.38(9H, s), 1.27(3H, t, J=6.9 Hz).
EXAMPLE 14 (E)-8-(4-Acetoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 14)
Substantially the same procedure as in Example 1 was repeated using 600 mg (1.76 mmol) of Compound g obtained in Reference Example 7. The obtained crude product was recrystallized from ethyl acetate to give 399 mg (59% yield) of Compound 14 as white crystals.
Melting Point:197.7°-198.1° C. Elemental Analysis:C20 H22 N4 O4 Calcd. (%):C 62.82, H 5.80,N 14.65 Found (%):C 62.69, H 5.77,N 14.65 IR(KBr) νmax (cm-1):1760, 1694, 1659, 1543, 1223. NMR (270 MHz; CDCl3) δ(ppm):7.78(1H, d, J=15.8 Hz), 7.60(2H, d, J=8.6 Hz), 7.15(2H, d, J=8.6 Hz), 6.87(1H, d, J=15.8 Hz), 4.22(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.06(3H, s), 2.33(3H, s), 1.39(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz).
EXAMPLE 15 (E)-8-(4-Acetoxy-3-methoxystyryl)-1,3-diallyl-7-methylxanthine (Compound 15)
Substantially the same procedure as in Example 1 was repeated using 800 mg (2.03 mmol) of Compound i obtained in Reference Example 9. The obtained crude product was recrystallized from toluene to give 830 mg (94% yield) of Compound 15 as white crystals.
Melting Point:207.0°-208.0° C. Elemental Analysis:C23 H24 N4 O5 Calcd. (%):C 63.29, H 5.54,N 12.84 Found (%):C 63.53, H 5.31,N 12.51 IR(KBr) νmax (cm-1):1752, 1657, 1644, 1511, 1203. NMR (270 MHz; DMSO-d6) δ(ppm):7.66(1H, d, J=15.8 Hz), 7.56(1H, s), 7.40(1H, d, J=8.3 Hz), 7.37(1H, d, J=15.8 Hz), 7.14(1H, d, J=8.3 Hz), 5.98-5.82(2H, m), 5.18-5.04(4H, m), 4.64(2H, d, J=5.3 Hz), 4.49(2H, d, J=5.3 Hz), 4.06(3H, s), 3.86(3H, s), 2.27(3H, s).
EXAMPLE 16 (E)-8-(3-Acetoxy-4-methoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 16)
Substantially the same procedure as in Example 1 was repeated using 1.00 g (2.70 mmol) of Compound j obtained in Reference Example 10. The obtained crude product was recrystallized from ethyl acetate to give 807 mg (72% yield) of Compound 16 as pale yellow crystals.
Melting Point:241.3°-241.9° C. Elemental Analysis:C21 H24 N4 O5 Calcd. (%):C 61.16, H 5.86,N 13.58 Found (%):C 61.08, H 6.07,N 13.80 IR(KBr) νmax (cm-1):1759, 1694, 1659, 1543, 1515, 1440, 1273, 1220. NMR (270 MHz; CDCl3) δ(ppm):7.71(1H, d, J=15.8 Hz), 7.40(1H, dd, J=8.6, 2.3 Hz), 7.32(1H, d, J=2.3 Hz), 6.99(1H, d, J=8.6 Hz), 6.75(1H, d, J=15.8 Hz), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.04(3H, s), 3.88(3H, s), 2.35(3H, s), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz).
EXAMPLE 17 (E)-8-(4-Acetoxy-3,5-dimethoxystyryl)-1, 3-diethyl-7-methylxanthine (Compound 17)
Substantially the same procedure as in Example 1 was repeated using 1.50 g (3.75 mmol) of Compound k obtained in Reference Example 11. The obtained crude product was recrystallized from ethanol/N, N-dimethylformamide to give 1.13 g (68% yield) of Compound 17 as yellow powders.
Melting Point:248.4°-248.9° C. Elemental Analysis:C22 H26 N4 O6 Calcd. (%):C 59.72, H 5.92,N 12.66 Found (%):C 59.85, H 6.22,N 12.64 IR(KBr) νmax (cm-1):1689, 1659, 1597, 1340, 1190, 1129. NMR (270 MHz; CDCl3) δ(ppm):7.73(1H, d, J=15.8 Hz), 6.83(1H, d, J=15.8 Hz), 6.81(2H, s), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.08(3H, s), 3.89(6H, s), 2.36(3H, s), 1.39(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz).
EXAMPLE 18 (E)-8-(4-Benzoyloxy-3,5-dimethoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 18)
Substantially the same procedure as in Example 2 was repeated using 1.50 g (3.75 mmol) of Compound k obtained in Reference Example 11. The obtained crude product was recrystallized from toluene/cyclohexane to give 1.16 g (61% yield) of Compound 18 as pale yellow crystals.
Melting Point:195.7°-196.320 C. Elemental Analysis:C27 H28 N4 O6 Calcd. (%):C 64.28, H 5.59,N 11.10 Found (%):C 64.16, H 5.61,N 11.03 IR(KBr) νmax (cm-1):1740, 1699, 1658, 1653, 1508, 1342. NMR (270 MHz; CDCl3) δ(ppm):8.24(2H, dd, J=7.9, 1.7 Hz), 7.76(1H, d, J=15.8 Hz), 7.65(1H, dt, J=7.9, 1.7 Hz), 7.52(2H, t, J=7.9 Hz), 6.87(1H, d, J=15.8 Hz), 6.86(2H, m), 4.22(2H, q, J=6.9 Hz), 4.10(2H, q, J=6.9 Hz), 4.09(3H, s), 3.87(6H, s), 1.40(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz).
EXAMPLE 19 (E)-8-(4-Acetoxy-3,5-dimethoxystyryl)-1,3-diallyl-7-methylxanthine (Compound 19)
Substantially the same procedure as in Example 1 was repeated using 1.19 g (2.81 mmol) of Compound m obtained in Reference Example 12. The obtained crude product was recrystallized from ethanol/N, N-dimethylformamide to give 680 mg (52% yield) of Compound 19 as white powders.
Melting Point:220.5°-221.1° C. Elemental Analysis:C24 H26 N4 O6 Calcd. (%):C 61.79, H 5.62,N 12.01 Found (%):C 61.74, H 5.78,N 12.07 IR (KBr) νmax (cm-1):1762, 1708, 1671, 1610, 1137. NMR (270 MHz; CDCl3) δ(ppm):7.73(1H, d, J=15.8 Hz), 6.82(1H, d, J=15.8 Hz), 6.81(2H, s), 6.11-5.87(2H, m), 5.35-5.17(4H, m), 4.76(2H, d, J=5.4 Hz), 4.65(2H, d, J=5.4 Hz), 4.08(3H, s), 3.89(6H, s), 2.36(3H, s).
EXAMPLE 20 (E)-1,3-Diallyl-8-(4-benzoyloxy-3,5-dimethoxystyryl)-7-methylxanthine (Compound 20)
Substantially the same procedure as in Example 2 was repeated using 1.00 g (2.36 mmol) of Compound m obtained in Reference Example 12. The obtained crude product was recrystallized from toluene/cyclohexane to give 990 mg (79% yield) of Compound 20 as white powders.
Melting Point:178.6°-179.8° C. Elemental Analysis:C29 H28 N4 O6 Calcd. (%):C 65.90, H 5.34,N 10.60 Found (%):C 66.00, H 5.40,N 10.58 IR(KBr) νmax (cm-1):1737, 1699, 1665, 1593, 1434, 1341, 1267, 1254. NMR (270 MHz; CDCl3) δ(ppm):8.23(2H, dd, J=7.4, 1.5 Hz), 7.77(1H, d, J=15.8 Hz), 7.65(1H, dt, J=7.4, 1.5 Hz), 7.52(2H, t, J=7.4 Hz), 6.86(1H, d, J=15.8 Hz), 6.85(2H, s), 6.11-5.88(2H, m), 5.36-5.18(4H, m), 4.77(2H, d, J=5.4 Hz), 4.65(2H, d, J=5.4 Hz), 4.09(3H, s), 3.87(6H, s).
EXAMPLE 21 (E)-8-(3-Acetoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 21)
Substantially the same procedure as in Example 1 was repeated using 3.00 g (8.81 mmol) of Compound n obtained in Reference Example 13. The obtained crude product was recrystallized from ethyl acetate to give 2.80 g (86% yield) of Compound 21 as white crystals.
Melting Point:206°-207° C. Elemental Analysis:C20 H22 N4 O4 Calcd. (%):C 62.80, H 5.80,N 14.65 Found (%):C 62.83, H 6.03,N 14.56 IR(KBr) νmax (cm-1):1781, 1711, 1683, 1565, 1516, 1466. NMR (270 MHz; DMSO-d6) δ(ppm):7.65(1H, d, J=15.8 Hz), 7.65(1H, s), 7.63(1H, d, J=8.3 Hz), 7.45(1H, t, J=8.3 Hz), 7.39(1H, d, J=15.8 Hz), 7.13(1H, d, J=8.3 Hz),4.07(2H, q, J=6.9 Hz), 4.04(3H, s, 3.92(2H, q, J=6.9 Hz), 2.30(3H, s) 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz).
EXAMPLE 22 (E)-8-(3-Benzoyloxystyryl)-1,3-diethyl-7-methylxanthine (Compound 22)
Substantially the same procedure as in Example 2 was repeated using 800 mg (2.23 mmol) of Compound n obtained in Reference Example 13. The obtained crude product was recrystallized from toluene/hexane to give 962 mg (97% yield) of Compound 22 as white powders.
Melting Point:223°-224° C. Elemental Analysis:C25 H24 N4 O4 Calcd. (%):C 67.55, H 5.44,N 12.61 Found (%):C 67.63, H 5.68,N 12.43 IR(KBr) νmax (cm-1):1748, 1606, 1516, 1456, 1422. NMR (270 MHz; CDCl3) δ(ppm):8.21(2H, dd, J=8.3, 1.5 Hz), 7.81(1H, d, J=15.3 Hz), 7.67(1H, t, J=7.4 Hz), 7.46-7.57(5H, m), 7.20-7.24(1H, m), 6.93(1H, d, J=15.3 Hz), 4.21(2H, q, J=6.9 Hz), 4.08(2H, q, J=6.9 Hz), 4.06(3H, s), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz).
EXAMPLE 23 (E)-8-(2-Acetoxy-5-methoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 23)
Substantially the same procedure as in Example 1 was repeated using 3.00 g (8.10 mmol) of Compound o obtained in Reference Example 14. The obtained crude product was recrystallized from ethyl acetate to give 3.25 g (97% yield) of Compound 23 as yellow crystals.
Melting Point:186°-187° C. Elemental Analysis:C21 H24 N4 O5 Calcd. (%):C 61.15, H 5.87,N 13.59 Found (%):C 61.24, H 6.21,N 13.75 IR(KBr) νmax (cm-1):1767, 1672, 1613, 1492, 1454, 1426. NMR. (270 MHz; DMSO-d6) δ(ppm):7.76(1H, d, J=15.8 Hz), 7.15(1H, d, J=3.0 Hz), 7.05(1H, d, J=8.9 Hz), 6.92(1H, dd, J=3.0, 8.9 Hz), 6.89(1H, d, J=15.8 Hz), 4.20(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.04(3H, s), 3.86(3H, s), 2.37(3H, s), 1.37(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz).
EXAMPLE 24 (E)-8-(2-Benzoyloxy-5-methoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 24)
Substantially the same procedure as in Example 2 was repeated using 800 mg (2.16 mmol) of Compound o obtained in Reference Example 14. The obtained crude product was recrystallized from N,N-dimethylformamide/water to give 972 mg (95% yield) of Compound 24 as yellow powders.
Melting Point:254°-255° C. Elemental Analysis:C26 H26 N4 O5 Calcd. (%):C 65.81, H 5.52,N 11.81 Found (%):C 65.81, H 5.74,N 11.73 IR(KBr) νmax (cm-1):1744, 1614, 1559, 1521, 1425. NMR (270 MHz; CDCl3) δ(ppm):8.27(2H, dd, J=7.6, 1.3 Hz), 7.81(1H, d, J=15.8 Hz), 7.68(1H, dt, J=1.3, 7.6 Hz), 7.54(2H, t, J=7.6 Hz), 7.21(1H, d, J=8.9 Hz), 7.18(1H, d, J=3.3 Hz), 6.96(1H, dd, J=3.3, 8.9 Hz), 6.93(1H, d, J=15.8 Hz), 4.10(2H, q, J=6.9 Hz), 4.05(2H, q, J=6.9 Hz), 3.88(3H, s), 3.83(3H, s), 1.24(3H, t, J=6.9 Hz), 1.23(3H, t, J=6.9 Hz).
EXAMPLE 25 (E)-8-(2-Acetoxy-3-methoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 25)
Substantially the same procedure as in Example 1 was repeated using 2.00 g (5.40 mmol) of Compound p obtained in Reference Example 15. The obtained crude product was recrystallized from ethyl acetate to give 2.01 g (90% yield) of Compound 25 as white crystals.
Melting Point:201.5°-202.8° C. Elemental Analysis:C21 H24 N4 O5 Calcd. (%):C 61.16, H 5.86,N 13.58 Found (%):C 61.04, H 6.09,N 13.45 IR(KBr) νmax (cm-1):1765, 1695, 1657, 1544, 1444, 1280. NMR (270 MHz; CDCl3) δ(ppm):7.80(1H, d, J=15.8 Hz), 7.30-7.21(2H, m), 6.98(1H, dd, J=6.9, 2.3 Hz), 6.93(1H, d, J=15.8 Hz), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.04(3H, s), 3.86(3H, s), 2.41(3H, s), 1.38(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz).
EXAMPLE 26 (E)-8-(2,3-Diacetoxystyryl)-1,3-diethyl-7-methylxanthine (Compound 26)
Substantially the same procedure as in Example 1 was repeated using 685 mg (1.92 mmol) of Compound q obtained in Reference Example 16. The obtained crude product was recrystallized from ethyl acetate to give 601 mg (71% yield) of Compound 26 as pale brown crystals.
Melting Point:228.3°-230.2° C. Elemental Analysis:C22 H24 N4 O6 Calcd. (%):C 59.99, H 5.49,N 12.72 Found (%):C 59.86, H 5.72,N 12.73 IR(KBr) νmax (cm-1):1769, 1692, 1665, 1220. NMR (270 MHz; CDCl3) δ(ppm):7.77(1H, d, j=15.8 Hz), 7.57(1H, dd, J=7.9, 1.7 Hz), 7.31(1H, t, J=7.9 Hz), 7.22(1H, dd, J=7.9, 1.7 Hz), 6.93(1H, d, J=15.8 Hz), 4.20(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.05(3H, s), 2.39(3H, s), 2.31(3H, s), 1.37(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz).
EXAMPLE 27 (E)-8-(3-Acetoxy-4,5-methylenedioxystyryl)-1,3-diethyl-7-methylxanthine (Compound 27)
Substantially the same procedure as in Example 1 was repeated using 2.00 g (5.02 mmol) of Compound r obtained in Reference Example 17. The obtained crude product was purified by silica gel column chromatography to give 471 mg (22% yield) of Compound 27 as a yellow solid, which was recrystallized from dioxane/water to give yellow powders.
Melting Point:>270° C. Elemental Analysis:C21 H22 N4 O6 Calcd. (%):C 59.15, H 5.20,N 13.14 Found (%):C 59.13, H 5.31,N 13.07 IR(KBr) νmax (cm-1):1709, 1673, 1520, 1460, 1309. NMR (270 MHz; CDCl3) δ(ppm):7.66(1H, d, J=15.8 Hz), 6.98(1H, d, J=1.7 Hz), 6.88(1H, d, J=1.7 Hz), 6.73(1H, d, J=15.8 Hz), 6.06(2H, s), 4.20(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.04(3H, s), 2.34(3H, s), 1.37(3H, t, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz).
REFERENCE EXAMPLE 1 (E)-8-(3,4-Dihydroxystyryl)-7-methyl-1,3-dipropylxanthine (Compound a)
Boron tribromide (5.6 ml, 5.6 mmol) in 1.0M methylene chloride solution was added to an ice-cooled solution of 770 mg (1.87 mmol) of (E)-8-(3, 4-dimethoxystyryl)-7-methyl-1, 3-dipropylxanthine (WO92/06976) in 15 ml of methylene chloride in an atmosphere of argon, followed by stirring at room temperature overnight. Methanol was added to the reaction mixture, followed by partitioning between chloroform and sodium hydrogen carbonate solution. The organic layer was washed with saturated aqueous sodium chloride, and dried over anhydrous sodium sulfate. The solvent was removed by evaporation, and the residue was purified by silica gel column chromatography to give 550 mg (77% yield) of Compound a as a yellow solid, which was micropowdered by ether to give yellow powders.
Melting Point:250.1°-251.4° C. Elemental Analysis:C20 H24 N4 O4 Calcd. (%):C 62.49, H 6.29, N 14.57 Found (%):C 62.27, H 6.48, N 14.74 IR(KBr) νmax (cm-1):1680, 1640, 1543, 1306. NMR (270 MHz; DMSO-d6) δ(ppm):9.31(1H, brs), 8.95(1H, brs), 7.49(1H, d, J=15.8 Hz), 7.15(1H, d, J=2.0 Hz), 7.04(1H, dd, J=7.9, 2.0 Hz), 6.98(1H, d, J=15.8 Hz), 6.78(1H, d, J=7.9 Hz), 3.99(2H, t, J=7.6 Hz), 3.98(3H, s), 3.84(2H, t, J=7.4 Hz), 1.73(2H, m), 1.57(2H, m), 0.90(3H, t, J=7.4 Hz), 0.87(3H, t, J=7.4 Hz).
RFERENCE EXAMPLE 2 (E)-8-(3-Hydroxy-4-methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound b)
Compound a (500 mg, 1.30 mmol) obtained in Reference Example 1 was dissolved in 10 ml of dimethylformamide, and methyl iodide (0.40 ml, 6.43 mmol) and lithium carbonate (400 mg, 6.50 mmol) were added thereto, followed by heating at 80° C. for 5 hours. Water was added to the reaction mixture to dissolve lithium carbonate, and the resulting precipitate was collected by filtration. The obtained crude product was dissolved in chloroform, and the solution was washed with saturated aqueous sodium chloride. The solvent was removed by evaporation, and the residue was purified by silica gel column chromatography, and subsequently recrystallized from hexane/ethyl acetate to give 162 mg (31% yield) of Compound b as yellow crystals.
Melting Point:200.3°-203.6° C. EI-MS (m/z):398(M+) IR(KBr) νmax (cm-1):1683, 1642, 1512, 1278. NMR (270 MHz; DMSO-d6) δ(ppm):8.98(1H, brs), 7.52(1H, d, J=15.5 Hz), 7.22(1H, d, J=2.0 Hz), 7.15(1H, dd, J=8.3, 2.0 Hz), 7.06(1H, d, J=15.5 Hz), 6.96(1H, d, J=8.3 Hz), 4.02-3.97(2H, m), 4.00(3H, s), 3.84-3.82(2H, m), 3.82(3H, s), 1.80-1.50(4H, m), 0.90(3H, t, J=7.3 Hz), 0.87(3H, t, J=7.3 Hz).
REFERENCE EXAMPLE 3 (E)-8-(3-Methoxy-4-methoxymethoxystyryl)-1,3-dipropylxanthine (Compound c)
3-Methoxy-4-methoxymethoxy cinnamic acid (4.63 g, 19.4 mmol) and 3-(3-diethylaminopropyl)-1-ethylcarbodiimido hydrochloride (5.08 g) were added to a mixed solution of 4.00 g (17.7 mmol) of 5,6-diamino-1,3-dipropyluracil J. Med. Chem., 28, 487 (1985)! in 50 ml of dioxane/25 ml of water. The solution was stirred at room temperature for 1 hour while adjusting to pH 5.5. The reaction mixture was cooled to room temperature, then 1.59 g of sodium hydroxide and 2N sodium hydroxide solution (50 ml) were added thereto. The mixture was heated under reflux for 1 hour, followed by cooling. The mixture was neutralized by adding 2N hydrochloric acid and the resulting precipitate was collected by filtration. The obtained crude product was recrystallized from dioxane/water to give 5.06 g (67% yield) of Compound c as pale yellow crystals.
Melting Point:226.7°-227.4° C. Elemental Analysis:C22 H28 N4 O5 Calcd. (%):C 61.67, H 6.58, N 13.08 Found (%):C 61.56, H 6.68, N 13.09 IR(KBr) νmax (cm-1):1697, 1655, 1650, 1516, 1255. NMR (270 MHz; DMSO-d6) δ(ppm):13.47(1H, brs), 7.60(1H, d, J=16.5 Hz), 7.31(1H, s), 7.10(2H, m), 7.00(1H, d, J=16.5 Hz), 5.19(2H, s), 3.98(2H, t, J=6.9 Hz), 3.88-3.83(5H, m), 3.40(3H, s), 1.79-1.66(2H, m), 1.62-1.51(2H, m), 0.90(3H, t, J=7.6 Hz), 0.88(3H, t, J=7.6 Hz).
REFERENCE EXAMPLE 4 (E)-8-(3-Methoxy-4-methoxymethoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound d)
Compound c (4.5 g, 10.5 mmol) obtained in Reference Example 3 was dissolved in 90 ml of dimethylformamide, and potassium carbonate (3.63 g, 26.26 mmol) and methyl iodide (1.31 ml, 21.04 mmol) were added thereto, followed by stirring at 50° C. for 1 hour. After cooling, water was added to the reaction mixture, and the resulting precipitate was collected by filtration. The obtained crude product was recrystallized from hexane/ethyl acetate to give 3.66 g (79% yield) of Compound d as pale yellow crystals.
Mealting Point:153.2°-154.9° C. Elemental Analysis:C23 H30 N4 O5 Calcd. (%):C 62.43, H 6.83, N 12.66 Found (%):C 62.42, H 6.95, N 13.05 IR(KBr) νmax (cm-1):1697, 1656, 1544, 1254. NMR (270 MHz; CDCl3) δ(ppm):7.73(1H, d, J=15.8 Hz), 7.20-7.13(2H, m), 7.10(1H, m), 6.78(1H, d, J=15.8 Hz), 5.28(2H, s), 4.14-4.08(2H, m), 4.06(3H, s), 4.01-3.97(2H, m), 3.96(3H, s), 3.53(3H, s), 1.91-1.77(2H, m), 1.76-1.63(2H, m), 1.01(3H, t, J=7.6 Hz), 0.97(3H, t, J=7.6 Hz).
REFERENCE EXAMPLE 5 (E)-8-(4-Hydroxy-3-methoxystyryl)-7-methyl-1,3-dipropylxanthine (Compound e)
Compound d (3.00 g, 6.78 mmol) obtained in Reference Example 4 was suspended in 60 ml of tetrahydrofuran, and 2N hydrochloric acid (17 ml) was added thereto, followed by heating under reflux for 1 hour. The reaction mixture was neutralized by adding 2N sodium hydroxide under ice-cooling. Water was added to the reaction mixture, and the resulting precipitate was collected by filtration. The obtained crude product was recrystallized from hexane/ethyl acetate to give 1.93 g (72% yield) of Compound e as pale yellow crystals.
Melting Point:186.8°-187.9° C. Elemental Analysis:C21 H26 N4 O4 Calcd. (%):C 63.30, H 6.57, N 14.06 Found (%):C 63.19, H 6.69, N 14.25 IR(KBr) νmax (cm-1):1693, 1650, 1540, 1520, 1284. NMR (270 MHz; DMSO-d6) δ(ppm):9.44(1H, brs), 7.57(1H, d, J=15.5 Hz), 7.39(1H, s), 7.19(1H, d, J=8.3 Hz), 7.13(1H, d, J=15.5 Hz), 6.81(1H, d, J=8.3 Hz), 4.01(3H, s), 3.99(2H, t, J=7.6 Hz), 3.86(3H, s), 3.84(2H, t, J=7.6 Hz), 1.77-1.66(2H, m), 1.63-1.50(2H, m), 0.90(3H, t, J=7.6 Hz), 0.87(3H, t, J=7.6 Hz).
Compounds of the following Reference Examples 6 to 16 were obtained from the corresponding uracil derivatives and cinnamic acid derivatives according to the procedures of Reference Examples 3 to 5.
REFERENCE EXAMPLE 6 (E)-1,3-Diethyl-8-(4-hydroxy-3-methoxystyryl)-7-methylxanthine Compound f)
Melting Point:185.3°-186.5° C. (ethyl acetate) Elemental Analysis:C19 H22 N4 O4.H2 O Calcd. (%):C 58.75, H 6.23, N 14.42 Found (%):C 59.13, H 6.21, N 14.39 IR(KBr) νmax (cm-1):1687, 1657, 1650, 1515, 1276. NMR (270 MHz; DMSO-d6) δ(ppm):9.45(1H, brs), 7.59(1H, d, J=15.8 Hz), 7.39(1H, d, J=2.0 Hz), 7.19(1H, dd, J=7.9, 2.0 Hz), 7.14(1H, d, J=15.8 Hz), 6.81(1H, d, J=7.9 Hz), 4.06(2H, q, J=6.9 Hz), 4.02(3H, s), 3.91(2H, q, J=6.9 Hz), 3.86(3H, s), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz).
REFERENCE EXAMPLE 7 (E)-1,3-Diethyl-8-(4-hydroxystyryl)-7-methylxanthine (Compound g)
Melting Point:>270° C. (isopropanol) Elemental Analysis:C18 H20 N4 O3 Calcd. (%):C 63.52, H 5.92, N 16.46 Found (%):C 63.17, H 6.02, N 16.18 IR(KBr) νmax (cm-1):1696, 1636, 1607, 1517. NMR (270 MHz; DMSO-d6) δ(ppm):9.79(1H, s), 7.62(2H, d, J=8.3 Hz), 7.58(1H, d, J=15.8 Hz), 7.08(1H, d, J=15.8 Hz), 6.81(2H, d, J=8.3 Hz), 4.07(2H, q, J=6.9 Hz), 3.99(3H, s), 3.92(2H, q, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz).
REFERENCE EXAMPLE 8 (E)-1,3-Dipropyl-8-(3,5-dihydroxystyryl)-7-methylxanthine (Compound h)
EI-MS (m/z):384(M+) NMR (270 MHz; DMSO-d6) δ(ppm):9.37(2H, s), 7.45(1H, d, J=15.8 Hz), 7.13(1H, d, J=15.8 Hz), 6.59(2H, s), 6.28(1H, s), 4.01(3H, s), 4.10-3.81(4H, m), 1.76-1.53(4H, m), 0.93-0.84(6H, m).
REFERENCE EXAMPLE 9 (E)-1,3-Diallyl-8-(4-hydroxy-3-methoxystyryl)-7-methylxanthine (Compound i)
Melting Point:202.0°-203.0° C. (toluene/cyclohexane) Elemental Analysis:C21 H22 N4 O4 Calcd. (%):C 63.95, H 5.62,N 14.20 Found (%):C 64.05, H 5.80,N 13.98 IR(KBr) νmax (cm-1):1688, 1639, 1523, 1283. NMR (270 MHz; DMSO-d6) δ(ppm):9.47(1H, brs), 7.57(1H, d, J=15.5 Hz), 7.39(1H, s), 7.19(1H, d, J=7.3 Hz), 7.14(1H, d, J=15.5 Hz), 6.81(1H, d, J=7.9 Hz), 6.03-5.79(2H, m), 5.21-5.03(4H, m), 4.63(2H, d, J=4.6 Hz), 4.48(2H, d, J=4.6 Hz), 4.02(3H, s), 3.86(3H, s).
REFERENCE EXAMPLE 10 (E)-1,3-Diethyl-8-(3-hydroxy-4-methoxystyryl)-7-methylxanthine (Compound j)
Melting Point:204.5°-205.8° C. (ethyl acetate) Elemental Analysis:C19H22 N4 O4 Calcd. (%):C 61.61, H 5.98,N 15.13 Found (%):C 61.49, H 6.06,N 14.98 IR(KBr) νmax (cm-1):1689, 1653, 1515, 1442. NMR (270 MHz; DMSO-d6) δ(ppm):9.06(1H,brs), 7.53(1H, d, J=15.5 Hz), 7.23(1H, s), 7.17(1H, d, J=8.3 Hz), 7.08(1H, d, J=15.5 Hz), 6.96(1H, d, J=8.3 Hz), 4.06(2H, q, J=6.9 Hz), 4.00(3H, s), 3.92(2H, q, J=6.9 Hz), 3.82(3H, s), 1.25(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz).
REFERENCE EXAMPLE 11 (E)-1,3-Diethyl-8-(4-hydroxy-3,5-dimethoxystyryl)-7-methylxanthine (Compound k)
Melting Point:225.9°-226.4° C. (toluene/cyclohexane) Elemental Analysis:C20 H24 N4 O5 Calcd. (%):C 59.99, H 6.04,N 13.99 Found (%):C 59.89, H 6.08,N 13.94 IR(KBr) νmax (cm-1):1689, 1656, 1641, 1514, 1334. NMR (270 MHz; CDCl3) δ(ppm):7.71(1H, d, J=15.8 Hz), 6.82(2H, s), 6.75(1H, d, J=15.8 Hz), 5.75(1H, brs), 4.21(2H, q, J=6.9 Hz), 4.09(2H, q, J=6.9 Hz), 4.07(3H, s), 3.96(6H, s), 1.39(3H, t, J=6.9 Hz), 1.27(3H, t, J=6.9 Hz).
REFERENCE EXAMPLE 12 (E)-1,3-Diallyl-8-(4-hydroxy-3,5-dimethoxystyryl)-7-methylxanthine (Compound m)
Melting Point:239.2°-239.8° C. (2-propanol/water) Elemental Analysis:C22 H24 N4 O5 Calcd. (%):C 62.25, H 5.70,N 13.20 Found (%):C 61.86, H 5.73,N 13.11 IR(KBr) νmax (cm-1):1695, 1666, 1518, 1337, 1110. NMR (270 MHz; CDCl3) δ(ppm):7.71(1H, d, J=15.8 Hz), 6.82(2H, s), 6.74(1H, d, J=15.8 Hz), 6.10-5.87(2H, m), 5.74(1H, brs), 5.35-5.16(4H, m), 4.76(2H, d, J=5.6 Hz), 4.65(2H, d, J=5.6 Hz), 4.06(3H, s), 3.96(6H, s).
REFERENCE EXAMPLE 13 (E)-1,3-Diethyl-8-(3-hydroxystyryl)-7-methylxanthine (Compound
Melting Point:250°-251° C. Elemental Analysis:C18 H20 N4 O3.H2 O Calcd. (%):C 60.35, H 6.19,N 15.63 Found (%):C 60.68, H 6.28,N 15.60 IR%(KBr) νmax (cm-1):1763, 1714, 1670, 1632, 1586, 1518, 1422. NMR (270 MHz; DMSO-d6) δ(ppm):9.55(1H, s), 7.55(1H, d, J=15.8 Hz), 7,22(1H, d, J=15.8 Hz), 7.13-7.25(3H, m), 6.79(1H, d, J=6.9 Hz), 4.06(2H, q, J=6.9 Hz), 4.01(3H, s), 3.90(2H, q, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz).
REFERENCE EXAMPLE 14 (E)-1,3-Diethyl-8-(2-hydroxy-5-methoxystyryl)-7-methylxanthine Compound o)
Melting Point:248°-250° C. (N, N-dimethylformamide/water) Elemental Analysis:C19 H22 N4 O4.H2 O Calcd. (%):C 58.75, H 6.23,N 14.43 Found (%):C 58.81, H 6.62,N 14.54 IR(KBr) νmax (cm-1):1616, 1559, 1527, 1449, 1419. NMR (270 MHz; DMSO-d6) δ(ppm):9.63(1H, s), 7.93(1H, d, J=15.8 Hz), 7.33(1H, d, J=2.4 Hz), 7.28(1H, d, J=15.8 Hz), 6.83(1H, s), 6.81(1H, d, J=2.4 Hz), 4.07(2H, q, J=6.9 Hz), 4.01(3H, s), 3.91(2H, q, J=6.9 Hz), 3.75(3H, s), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz).
REFERENCE EXAMPLE 15 (E)-1,3-Diethy 1-8-(2-hydroxy-3-methoxystyry 1)-7-methylxanthine (Compound p)
Melting Point:225.4°-226.4° C. (dioxane/water) Elemental Analysis:C19 H22 N4 O4 Calcd. (%):C 61.61, H 5.98,N 15.13 Found (%):C 61.40, H 6.12,N 15.09 IR(KBr) νmax (cm-1):1758, 1721, 1507, 1328. NMR (270 MHz; DMSO-d6) δ(ppm):9.26(1H,brs), 8.01(1H, d, J=16.2 Hz), 7.40(1H, d, J=7.9 Hz), 7.24(1H, d, J=16.2 Hz), 6.97(1H, d, J=7.9 Hz), 6.83(1H, d, J=7.9 Hz), 4.07(2H, q, J=6.9 Hz), 4.00(3H, s), 3.92(2H, q, J=6.9 Hz), 3.84(3H, s), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz).
REFERENCE EXAMPLE 16 (E)-1,3-Diethyl-8-(2,3-dihydroxystyryl)-7-methylxanthine (Compound q)
Melting Point:242.2°-244.2° C. (dioxane/water) Elemental Analysis:C18 H20 N4 O4 ·0.6 H2 O Calcd. (%):C 58.88, H 5.82,N 15.26 Found (%):C 58.81, H 5.80,N 14.87 IR(KBr) νmax (cm-1):1691, 1642, 1543, 1437, 1279. NMR (270 MHz; DMSO-d6) δ(ppm):7.99(1H, d, J=15.8 Hz), 7.25(1H, d, J=7.6 Hz), 7.21(1H, d, J=15.8 Hz), 6.80(1H, d, J=7.6 Hz), 6.68(1H, t, J=7.6 Hz), 4.07(2H, q, J=6.9 Hz), 4.00(3H, s), 3.92(2H, q, J=6.9 Hz), 1.26(3H, t, J=6.9 Hz), 1.13(3H, t, J=6.9 Hz).
REFERENCE EXAMPLE 17 (E)-1,3-Diethyl-8-(3-hydroxy-4,5-methylenedioxystyryl)-7-methylxanthine (Compound r)
Substantially the same procedure as in Reference Example 1 was repeated using 500 mg (1.25 mmol) of (E)-1,3-diethyl-8-(3,4-methylenedioxy-5-methoxystyryl)-7-methylxanthine (Japanese Published Unexamined Patent Application No. 211856/94). The obtained crude product was purified by silica gel column chromatography to give 216 mg (45% yield) of Compound r as a yellow solid, which was finepowdered in ethanol to give yellow powders.
Melting Point:264.7°-268.2° C. Elemental Analysis:C19 H20 N4 O5. . 0.6 H2 O Calcd. (%):C 57.75, H 5.41,N 14.18 Found (%):C 57.90, H 5.60,N 13.95 IR(KBr) νmax (cm-1):1714, 1657, 1537, 1460. NMR (270 MHz; DMSO-d6) δ(ppm):9.85(1H, s), 7.47(1H, d, J=15.8 Hz), 7.12(1H, d, J=15.8 Hz), 7.05(1H, d, J=1.3 Hz), 6.75(1H, d, J=1.3 Hz), 6.02(2H, s), 4.06(2H, q, J=6.9 Hz), 4.00(3H, s), 3.91(2H, q, J=6.9 Hz), 1.25(3H, t, J=6.9 Hz), 1.12(3H, t, J=6.9 Hz).
PREPARATION EXAMPLE 1 Tablet
Tablets having the following composition are prepared according to a conventional method.
Prescription 
______________________________________                                    
Compound 4             20 mg                                              
Lactose                143.4 mg                                           
Potato starch          30 mg                                              
Hydroxypropyl cellulose                                                   
                       6 mg                                               
Magnesium stearate     0.6 mg                                             
                       200 mg                                             
______________________________________
PREPARATION EXAMPLE 2 Fine Granules
Fine granules having the following compositions are prepared according to a conventional method.
Prescription 
______________________________________                                    
Compound 5             20 mg                                              
Lactose                655 mg                                             
Corn starch            285 mg                                             
Hydroxypropyl cellulose                                                   
                       40 mg                                              
                       1,000 mg                                           
______________________________________
PREPARATION EXAMPLE 3 Capsules
Capsules having the following composition are prepared according to a conventional method.
Prescription 
______________________________________                                    
Compound 4             20 mg                                              
Avicel                 99.5 mg                                            
Magnesium stearate     0.5 mg                                             
                       120 mg                                             
______________________________________
PREPARATION EXAMPLE 4 Injectable Preparations
An injectable preparation having the following composition is prepared according to a conventional method.
Prescription 
______________________________________                                    
Compound 5              2 mg                                              
Purified soybean oil    200 mg                                            
Purified yolk lecithin  24 mg                                             
Injectable glucose solution                                               
                        50 mg                                             
Injectable distilled water                                                
                        1.72 ml                                           
                        2.00 ml                                           
______________________________________
PREPARATION EXAMPLE 5 Syrup
Syrup having the following composition is prepared according to a conventional method.
Prescription 
______________________________________                                    
Compound 4              20 mg                                             
Refined sucrose         30 mg                                             
p-hydroxybenzoic ethyl ester                                              
                        40 mg                                             
p-hydroxybenzoic propyl ester                                             
                        10 mg                                             
Strawberry flavor       0.1 ml                                            
Water                   99.8 ml                                           
                        100 ml                                            
______________________________________
EFFECT OF THE INVENTION
The present invention provides novel xanthine derivatives and pharmaceutically acceptable salts thereof which are useful for treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).

Claims (12)

We claim:
1. A xanthine derivative represented by Formula (I) or its pharmaceutically acceptable salt: ##STR33## wherein R1 and R2 independently represent lower alkyl, lower alkenyl, or lower alkynyl; R3 represents hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; R4 represents lower alkyl, or aryl which is optionally substituted with 1 to 4 substituents independently selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, halogen, nitro, amino, lower alkylamino, di-lower alkylamino, benzyloxy, phenyl and phenoxy, wherein said lower alkyl substituent and lower alkoxy substituent are each optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, nitro, lower alkoxy and amino; R5 and R6 independently represent hydrogen, lower alkyl, or lower alkoxy, or R5 and R6 are combined together to represent --O--(CH2)p --O-- (where p is an integer of 1 to 3); n represents 0, 1 or 4; and m represents 1 or 2, with the proviso that R1 and R2 are not methyl.
2. A compound of claim 1 wherein R1, R2, and R3 independently represent lower alkyl or lower alkenyl.
3. A compound of claim 1 wherein R3 represents lower alkyl.
4. A compound of claim 3 wherein R1 and R2 independently represent ethyl, propyl or allyl.
5. A compound of claim 4 wherein R3 represents methyl.
6. A compound of claim 5 wherein R4 represents methyl, ethyl, tert-butyl or phenyl.
7. A compound of claim 6 wherein R5 and R6 independently represent hydrogen, methoxy, or R5 and R6 are combined together to represent --O--CH2 --O--.
8. A compound of claim 2, wherein R3 represents lower alkyl.
9. A method for treatment of Parkinson's disease, comprising:
selecting a pharmaceutical composition containing at least one of the compounds of claims 1 to 7 or 8 and a pharmaceutically acceptable excipient; and
administering said composition to a patient in need thereof.
10. A composition comprising at least one of the compounds of claims 1 to 7 or 8 and a pharmaceutically acceptable carrier.
11. A method of producing a pharmaceutical composition, comprising the steps of:
selecting a compound according to any of claims 1 to 7 or 8, and
blending said compound with a pharmaceutically acceptable excipient.
12. A method of treating depression, comprising
selecting a pharmaceutical composition containing at least one of the compounds of claims 1 to 7 or 8 and a pharmaceutically acceptable excipient; and
administering said composition to a patient in need thereof.
US08/537,770 1994-02-23 1995-02-23 Xanthine derivatives Expired - Fee Related US5703085A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2573694 1994-02-23
JP6-025736 1994-02-23
PCT/JP1995/000267 WO1995023148A1 (en) 1994-02-23 1995-02-23 Xanthine derivative

Publications (1)

Publication Number Publication Date
US5703085A true US5703085A (en) 1997-12-30

Family

ID=12174110

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/537,770 Expired - Fee Related US5703085A (en) 1994-02-23 1995-02-23 Xanthine derivatives

Country Status (7)

Country Link
US (1) US5703085A (en)
EP (1) EP0698607B1 (en)
AT (1) ATE218139T1 (en)
AU (1) AU1823895A (en)
CA (1) CA2161011A1 (en)
DE (1) DE69526822T2 (en)
WO (1) WO1995023148A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6806270B2 (en) 1999-08-31 2004-10-19 Vanderbilt University Selective antagonists of A2B adenosine receptors
US20070078148A1 (en) * 2003-12-09 2007-04-05 Kyowa Hakko Kogyo Co., Ltd. Agents for preventing and/or treating higher brain dysfunctions
WO2007045705A2 (en) 2005-10-14 2007-04-26 Proyecto De Biomedicina Cima, S.L. Compounds for the treatment of auricular fibrillation
US20080170990A1 (en) * 2006-09-29 2008-07-17 Cv Therapeutics, Inc. Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
US20080213165A1 (en) * 2006-09-01 2008-09-04 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods
US20080221134A1 (en) * 2006-12-22 2008-09-11 Muller Christa E 8-alkynylxanthines and derivatives
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
EP2044940A2 (en) 2002-01-28 2009-04-08 Kyowa Hakko Kogyo Co., Ltd Methods of treating patients suffering from movement disorders
US20090286811A1 (en) * 2008-04-23 2009-11-19 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as trpv3 modulators
US20090317331A1 (en) * 2000-02-23 2009-12-24 Cv Therapeutics, Inc. Method of Identifying Partial Agonists of the A2A Receptor
US20100086483A1 (en) * 2008-09-29 2010-04-08 Gilead Palo Alto, Inc. Method of multidetector computed tomagraphy
US20100160620A1 (en) * 1999-06-22 2010-06-24 Gilead Palo Alto, Inc. N-pyrazole a2a receptor agonists
US20100179313A1 (en) * 2006-02-03 2010-07-15 Gilead Palo Alto, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US20100183503A1 (en) * 2002-07-29 2010-07-22 Gilead Palo Alto, Inc. Myocardial perfusion imaging methods and compositions
US20100272645A1 (en) * 2002-07-29 2010-10-28 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US20100292254A1 (en) * 2008-01-11 2010-11-18 Glenmark Pharmaceuticals, S.A. Fused Pyrimidine Derivatives as Trpv3 Modulators
US8106029B2 (en) 2004-10-20 2012-01-31 Gilead Sciences, Inc. Use of A2A adenosine receptor agonists
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814809B1 (en) * 1994-12-13 2003-08-13 Euroceltique S.A. Aryl thioxanthines
US6727259B2 (en) 1997-09-05 2004-04-27 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
FR2814077A1 (en) * 2000-09-20 2002-03-22 Inst Nat Sante Rech Med USE OF ADENOSINE RECEPTOR MODULATORS TO REGULATE THE FUNCTION OF NETRINS AND / OR THEIR RECEPTORS
CA2561383A1 (en) * 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Prophylactic and/or therapeutic agents for chronic musculoskeletal pain
KR20090094465A (en) * 2006-12-22 2009-09-07 슈바르츠 파르마 악티엔게젤샤프트 8-ethinylxanthine derivatives as selective a2a receptor antagonists
US10184028B2 (en) 2016-01-11 2019-01-22 Industrial Technology Research Institute Method for preparing a polymer
US10287396B2 (en) 2016-01-11 2019-05-14 Industrial Technology Research Institute Polymer
US9994679B2 (en) * 2016-01-11 2018-06-12 Industrial Technology Research Institute Polymerization process of polyarylene sulfide
US10377705B2 (en) 2016-01-11 2019-08-13 Industrial Technology Research Institute Method for preparing polyarylene sulfide (PAS) monomer
CN111333648B (en) * 2019-04-24 2021-05-11 东莞市东阳光新药研发有限公司 8-substituted aromatic ring vinyl xanthine derivative and application thereof
CN113248505B (en) * 2021-06-09 2021-09-21 南京安杰新生物医药有限公司 Preparation method of istradefylline for removing methyl impurities

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559893A1 (en) * 1990-10-18 1993-09-15 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivative
EP0565377A1 (en) * 1992-04-08 1993-10-13 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agents for use in the treatment of parkinson's disease
DE4325254A1 (en) * 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Unsymmetrically substituted xanthines
EP0590919A1 (en) * 1992-09-28 1994-04-06 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agents for parkinson's disease
EP0607607A1 (en) * 1992-12-24 1994-07-27 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
EP0628311A1 (en) * 1992-07-08 1994-12-14 Kyowa Hakko Kogyo Co., Ltd. Antidepressant

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559893A1 (en) * 1990-10-18 1993-09-15 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivative
EP0565377A1 (en) * 1992-04-08 1993-10-13 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agents for use in the treatment of parkinson's disease
EP0628311A1 (en) * 1992-07-08 1994-12-14 Kyowa Hakko Kogyo Co., Ltd. Antidepressant
DE4325254A1 (en) * 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Unsymmetrically substituted xanthines
EP0590919A1 (en) * 1992-09-28 1994-04-06 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agents for parkinson's disease
EP0607607A1 (en) * 1992-12-24 1994-07-27 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Jacobsen J. Med. Chem., vol. 36, No. 10 (1993) 1333 42. *
Jacobsen J. Med. Chem., vol. 36, No. 10 (1993) 1333-42.
Kato s Integrated English Japanese Medical Dictionary (Nanzando, 1979) p. 757. *
Kato's Integrated English-Japanese Medical Dictionary (Nanzando, 1979) p. 757.

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045519B2 (en) 1999-06-22 2015-06-02 Gilead Sciences, Inc. N-pyrazole A2A receptor agonists
US20100160620A1 (en) * 1999-06-22 2010-06-24 Gilead Palo Alto, Inc. N-pyrazole a2a receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6806270B2 (en) 1999-08-31 2004-10-19 Vanderbilt University Selective antagonists of A2B adenosine receptors
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
US9163057B2 (en) 2000-02-23 2015-10-20 Gilead Sciences, Inc. Methods of myocardial perfusion imaging
US8071566B2 (en) 2000-02-23 2011-12-06 Gilead Sciences, Inc. Methods of coronary imaging
US20090317331A1 (en) * 2000-02-23 2009-12-24 Cv Therapeutics, Inc. Method of Identifying Partial Agonists of the A2A Receptor
EP2260850A2 (en) 2002-01-28 2010-12-15 Kyowa Hakko Kogyo Co., Ltd A2A receptor antogonists for use in the treatment of movement disorders
EP2044940A2 (en) 2002-01-28 2009-04-08 Kyowa Hakko Kogyo Co., Ltd Methods of treating patients suffering from movement disorders
EP2942082A2 (en) 2002-01-28 2015-11-11 Kyowa Hakko Kogyo Co., Ltd A2A receptor antogonists for use in the treatment of movement disorders
US8906878B2 (en) 2002-07-29 2014-12-09 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US9289446B2 (en) 2002-07-29 2016-03-22 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20100183503A1 (en) * 2002-07-29 2010-07-22 Gilead Palo Alto, Inc. Myocardial perfusion imaging methods and compositions
US20100272645A1 (en) * 2002-07-29 2010-10-28 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US8183226B2 (en) 2002-07-29 2012-05-22 Gilead Sciences, Inc. Myocardial perfusion imaging method
US8133879B2 (en) 2002-07-29 2012-03-13 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20070078148A1 (en) * 2003-12-09 2007-04-05 Kyowa Hakko Kogyo Co., Ltd. Agents for preventing and/or treating higher brain dysfunctions
US8106029B2 (en) 2004-10-20 2012-01-31 Gilead Sciences, Inc. Use of A2A adenosine receptor agonists
WO2007045705A2 (en) 2005-10-14 2007-04-26 Proyecto De Biomedicina Cima, S.L. Compounds for the treatment of auricular fibrillation
US7956179B2 (en) 2006-02-03 2011-06-07 Gilead Sciences, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US8106183B2 (en) 2006-02-03 2012-01-31 Gilead Sciences, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
USRE47301E1 (en) 2006-02-03 2019-03-19 Gilead Sciences, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US9085601B2 (en) 2006-02-03 2015-07-21 Gilead Sciences, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US8268988B2 (en) 2006-02-03 2012-09-18 Gilead Sciences, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US8524883B2 (en) 2006-02-03 2013-09-03 Gilead Sciences, Inc. Monohydrate of (1-{9-[4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide
US20100179313A1 (en) * 2006-02-03 2010-07-15 Gilead Palo Alto, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US20080213165A1 (en) * 2006-09-01 2008-09-04 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
US20080170990A1 (en) * 2006-09-29 2008-07-17 Cv Therapeutics, Inc. Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
US20080221134A1 (en) * 2006-12-22 2008-09-11 Muller Christa E 8-alkynylxanthines and derivatives
US8044061B2 (en) 2006-12-22 2011-10-25 Ucb Pharma Gmbh 8-alkynylxanthines and derivatives
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
US8349846B2 (en) 2008-01-11 2013-01-08 Glenmark Pharmaceuticals, S.A. Fused pyrimidine derivatives as TRPV3 modulators
US20100292254A1 (en) * 2008-01-11 2010-11-18 Glenmark Pharmaceuticals, S.A. Fused Pyrimidine Derivatives as Trpv3 Modulators
US20090286811A1 (en) * 2008-04-23 2009-11-19 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as trpv3 modulators
US8518955B2 (en) 2008-04-23 2013-08-27 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
US20100086483A1 (en) * 2008-09-29 2010-04-08 Gilead Palo Alto, Inc. Method of multidetector computed tomagraphy

Also Published As

Publication number Publication date
EP0698607B1 (en) 2002-05-29
DE69526822D1 (en) 2002-07-04
WO1995023148A1 (en) 1995-08-31
EP0698607A4 (en) 1996-03-27
CA2161011A1 (en) 1995-08-31
EP0698607A1 (en) 1996-02-28
ATE218139T1 (en) 2002-06-15
DE69526822T2 (en) 2003-01-23
AU1823895A (en) 1995-09-11

Similar Documents

Publication Publication Date Title
US5703085A (en) Xanthine derivatives
JP2613355B2 (en) Parkinson&#39;s disease treatment
US5587378A (en) Therapeutic agent for Parkinson&#39;s disease
US5543415A (en) Antidepressants
CA2024381C (en) Xanthine compounds
US5525607A (en) Xanthine compounds
EP0607607B1 (en) Xanthine derivatives
US6531600B1 (en) Treatment and compounds
EP0258191B1 (en) Xanthine derivatives
JP2613352B2 (en) Parkinson&#39;s disease treatment
EP0559893B1 (en) Xanthine derivative
JP2012500805A (en) 6-Substituted 2- (benzimidazolyl) purine and purinone derivatives and 6-substituted 2- (imidazolo [4,5-c] pyridinyl) purine and prinone derivatives for immunosuppression
EP0449175B1 (en) Selective adenosine receptor agents
JP2988692B2 (en) Imidazoquinolone derivative
JP2988683B2 (en) Imidazoquinolone derivative
US5336769A (en) Xanthine derivatives
JPH06247942A (en) Piperazine derivative
US5281605A (en) Novel xanthine derivatives
JP2843671B2 (en) Xanthine derivative
JPH06102660B2 (en) Novel morpholine derivatives and pharmaceutical compositions containing these derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: KYOWA HAKKO KOGYO CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUZUKI, FUMIO;KOIKE, NOBUAKI;SHIMADA, JUNICHI;AND OTHERS;REEL/FRAME:007750/0981;SIGNING DATES FROM 19950929 TO 19951009

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20051230